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ABSTRACT 
The pathology of aging-associated neurodegenerative disorders typically involves the 
occurrence of proteinaceous cytoplasmic inclusions in the brain. These inclusions are seen in 
both neurons and glial cells, affecting disease-specific cell populations. Most types of 
inclusions associated with cognitive or movement dysfunction are composed of cytoplasmic 
aggregates of tau or α-synuclein (αS) proteins in aberrant fibrillar forms, thus defining the 
disease groups of “tauopathies” and “synucleinopathies”. 
Inclusions are usually accompanied by cell loss, suggesting that their origin is closely 
linked to the neuronal death and dysfunction that are responsible for the clinical symptoms. 
The molecular events underlying the formation of cytoplasmic inclusions are poorly 
understood, but it is increasingly believed that the biogenesis of different types of inclusions 
may share some common mechanisms. In order to elucidate the mechanisms of inclusion 
formation and the elicited cellular reactions, it is necessary to identify key proteins involved 
and investigate their roles in these events. In particular, proteins that may contribute to or 
regulate the aggregation process are of interest. 
In the present series of studies, a gene array approach and cellular models were first 
utilized to identify proteins potentially involved in neurodegenerative phenomena (study I). 
Following the identification of p62, a signaling protein with several features of interest, the 
expression of this protein was examined in neuropathology-mimicking conditions in neuronal 
culture. Subsequently, the involvement of p62 was investigated in disease-associated protein 
aggregation in the human brain using immunohistochemistry (studies II−IV). In study II, 
brain specimens from different tauopathies (Alzheimer and Pick diseases) and 
synucleinopathies (Parkinson disease, dementia with Lewy bodies, and multiple system 
atrophy) were examined. In study III, the incorporation of p62 was studied in more detail 
with respect to the tau pathology of Alzheimer disease. In study IV, the morphogenesis of 
αS-containing inclusions characteristic of Parkinson disease was elucidated. 
The main findings were: I: The expression of p62 transcript and p62 protein were both 
prominently upregulated in response to pro-apoptotic conditions and proteasomal inhibition. 
This upregulation might indicate the activation of survival signaling. II: In both tauopathies 
and synucleinopathies, the p62 protein was copiously present in the hallmark cytoplasmic 
inclusions in perikarya but was mostly absent from intraneuritic deposits. III: In the tau 
pathology of Alzheimer disease, p62 was selectively incorporated into neurofibrillary tangles 
and represented a relatively early constituent in these structures. IV: The spectrum of 
perikaryal αS pathology in the substantia nigra pointed to a morphogenetic sequence in which 
punctate αS deposits, pale bodies, and Lewy bodies arise as successive stages of a complex 
aggregation process. The engagement of p62 coincided with the formation of compact 
inclusions, possibly as a part of a cytoprotective response. 
These findings are compatible with several alternative interpretations, but the pattern of 
p62 involvement in the various types of inclusions is viewed as evidence that p62 plays a 
contributory role in their formation. Since inclusions may serve as sinks for potentially 
noxious proteins, p62 may act to promote cell viability. 
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1. INTRODUCTION 
As life expectancy expands, society is faced with an increasing burden of patients with 
dementia and movement disability due to aging-associated neurodegenerative disorders 
(NDs). Few of the therapeutic possibilities currently available are able even to slow, let 
alone halt the progression of NDs. On the other hand, there is also a growing recognition 
that these diverse conditions appear to share many similar pathogenetic mechanisms, 
giving hope that if one could untangle these mechanisms, then it might be possible to 
devise novel therapeutic opportunities applicable to a host of different diseases. 
A conspicuous pathological feature shared by most of these disorders is the phenomenon 
of aberrant protein aggregation (Goedert et al. 1998). This process is manifest as the 
formation of inclusions, i.e., focal intracellular accumulations containing fibrillar forms 
of cellular proteins, in the cytoplasm or nuclei of cells within the central nervous system. 
Various types of inclusions have achieved major importance as neuropathological 
markers for the classification and postmortem diagnosis of NDs (Esiri et al. 1997, Lowe 
et al. 1997, Lowe 1998). From the methodological standpoint, the usefulness of 
inclusions stems from their conspicuous nature which, together with appropriate 
histological staining techniques, enables their unambiguous identification and 
quantitative assessment in tissue sections. From the viewpoint of diagnostics, the use of 
inclusions for postmortem diagnosis and for disease classification is justified by the 
consistent associations between some clinical phenotypes and the occurrence and 
distribution of certain inclusion types within specific cell types and areas of the brain. 
Adding to the utility of inclusions is the strikingly common involvement of “inclusion 
pathology” within the spectrum of NDs. Most of these disorders, including the most 
prevalent diseases, display characteristic types of inclusions with disease-dependent 
intrabrain distributions (Esiri et al. 1997, Lowe et al. 1997, Lowe 1998). 
In several of these diseases, the pathological aggregates are primarily composed of 
aberrant tau or α-synuclein proteins, which accumulate as fibrils into the cytoplasmic 
compartment of neurons and/or glia. These “tauopathies” (Lee et al. 2001b) and 
“synucleinopathies” (Jellinger 2003) account for most of the inclusion pathology 
associated with cognitive or movement dysfunction. 
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The formation of cytoplasmic inclusions is poorly understood (Alves-Rodrigues et al. 
1998, Goedert et al. 1998). A closely linked and likewise unclear issue is the relation of 
inclusions to cell loss that typically co-occurs in affected brain areas (Terry 2000). This 
co-occurrence with cell loss and the association to clinical manifestations, together with 
the wide involvement of inclusion pathology in NDs and the fact that most types of ND-
associated cytoplasmic inclusions share several common features, suggest that their 
formation is a fundamental process in the pathogenesis of NDs and may involve common 
mechanisms that are closely intertwined with the events underlying cell death. 
In particular, there is accumulating evidence to suggest that in several NDs, the cellular 
damage associated with protein aggregation might result from toxic actions exerted by 
fibrillar or non-fibrillar protein assemblies that arise due to aberrant conformational 
changes (Taylor et al. 2002, Caughey and Lansbury 2003), whereas the sequestration of 
such assemblies into compact inclusions might serve to counteract their noxiousness. 
This sequestration may involve active cellular processes such as microtubule-dependent 
transport for routing aggregated proteins to proteasomal/autophagic clearance (Kopito 
2000, Garcia-Mata et al. 2002), and ubiquitination that might prevent non-productive 
interactions (Gray 2001). Despite this emerging view of common mechanisms, wide gaps 
in our understanding of inclusion-related phenomena still remain, especially the chasm 
between in vitro-based models and observations made in human diseases. 
In order to better understand the pathogenetic events underlying the formation of 
inclusions and the cellular reactions elicited by protein aggregation, it is necessary to 
identify proteins that might have regulatory functions in these processes. Specifically, 
proteins with the ability to directly interact with aggregated proteins are of interest. 
The protein p62 (sequestosome 1) is a cytoplasmic protein for which physiological 
functions have been assigned in the context of signaling pathways activated by growth 
factors (Geetha and Wooten 2002). In the present series of studies, however, p62 was 
identified and selected for investigation as a protein displaying a number of features that 
suggested a possible role in neuropathological conditions. We therefore characterized the 
expression of p62 in neuropathology-mimicking cellular models and examined its 
involvement in disease-associated protein aggregation in the human brain.  
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2. REVIEW OF THE LITERATURE 
2.1 Cytoplasmic inclusions associated with neurodegenerative disorders 
The term ”inclusion” refers to abnormal accumulations of intracellular constituents, 
appearing as discrete bodies within the cell. Based on their primary material, location, 
and topography, inclusions can be broadly classified into lipid-, carbohydrate-, and 
protein-enriched types, into cytoplasmic and intranuclear types, and into membrane-
bound types and those without delimiting membranes. Both disease-associated inclusions 
and those for which no overt association to pathological conditions has been found to 
date are known. A range of NDs are associated with various types of cytoplasmic or 
intranuclear inclusions that primarily contain abnormal proteins, usually lack delimiting 
membranes, and typically populate specific cell types and areas of the brain (Esiri et al. 
1997, Lowe et al. 1997, Alves-Rodrigues et al. 1998). The remainder of this text is 
primarily concerned with the cytoplasmic subset of these disease-associated inclusions. 
The main emphasis will be on inclusions assumed to consist mainly of aberrant tau or α-
synuclein (αS) proteins. 
A growing number of cytoplasmic inclusion types have been discovered, due to 
increasing research interest and the improvements in the methods for their visualization 
in tissue sections. In early studies, inclusions could be visualized using histological stains 
with affinity for protein-rich material, such as silver impregnation techniques. Following 
the identification of the major protein constituents in the inclusions, the use of 
immunodetection has enabled a more sensitive and specific visualization, and facilitated 
the identification of novel (sub)types. 
It should be noted that although the term “inclusion” is often used interchangeably with 
“protein accumulation” or “protein aggregation“, the latter two terms denote related but 
different concepts. “Protein accumulation” refers to any type of protein buildup, whether 
focal or diffuse, intra- or extracellular. “Protein aggregation”, in turn, denotes the direct 
association of normally separate proteins into aberrant multimolecular assemblies, by 
means of any type of biochemical interaction (i.e., covalent, electrostatic, or 
hydrophobic). 
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2.1.1 Pathogenetic relevance 
The role of inclusions in the pathogenesis of NDs is still poorly understood. However, 
several lines of evidence suggest that inclusion formation is deeply intertwined with the 
pathological events that account for the clinical expression of these diseases. (1) Certain 
types of inclusion pathology correlate well with their respective clinical phenotypes 
(Gibb et al. 1991, Arriagada et al. 1992, Dickson 1998). (2) Inclusions typically co-occur 
with cell loss in the same brain areas, pointing to close interconnections between the 
aberrant events underlying cell death and inclusion formation (Feany and Dickson 1996, 
Bobinski et al. 1997, Castellani 1998, Dickson 1998, Braak and Braak 2000). (3) The 
wide involvement of inclusion pathology in NDs suggests that the formation of inclusions 
is a central process that may reflect similar mechanisms in the pathogenesis of these 
conditions. (4) Despite their varied patterns of disease association, cell type specificity, 
regional distribution, morphology, and protein composition, most types of cytoplasmic 
inclusions associated with NDs share a number of common features (Table 1), supporting 
the hypothesis that their formation may involve common pathological processes. 
Table 1.  Features shared by most types of ND-associated cytoplasmic inclusions. 
Occurrence • Associated with advanced age. 
• Spatially selective involvement of brain regions and cell types, manifest as 
characteristic predilection areas and vulnerable cell populations. 
Morphology  • Often voluminuous and localized adjacent to the nucleus, frequently causing an 
apparent displacement or indentation of the latter. 
Composition  • Proteinaceous, as evident from affinity to protein-binding dyes. 
• Immunoreactivity for ubiquitin. May reflect a failure of the ubiquitin-proteasome 
system, possibly promoting the accumulation of undegraded proteins. 
Ultrastructure  • Mostly composed of fibrillar material, constituted by aberrant assemblies of 
normal cytoplasmic proteins. 
• Absence of delimiting membranes. 
Protein 
conformations  
• The major protein constituents seem to have undergone aberrant conformational 
changes, often resulting in the enrichment of β-structure. 
Effect on host 
cell viability  
• Host cells appear to remain viable and active, as evidenced by the preservation of 
the cell membrane, nucleus, and metabolic markers. 
Associated 
pathology in 
 surrounding 
tissue  
• Typically co-occur with cell loss. 
• Frequently accompanied by astrocytosis and activation of microglia. 
• Several inclusion types are associated with abnormal neurites.  
 19 
For the above reasons, an intense research effort has been directed at elucidating the 
molecular nature and biogenesis of neuropathological inclusions, as well as their relation 
to neuronal dysfunction, cell loss, and clinical symptoms. If we could identify common 
degenerative processes and clarify the mechanisms relating to inclusions of a particular 
type, this would undoubtedly advance our understanding of the pathogenesis for the 
entire spectrum of “inclusion disorders” (Lee et al. 2001b). 
2.1.2 Mechanistic relation to cell death and neuronal dysfunction 
While abundant evidence points to a central position for inclusions in the pathogenesis of 
NDs, it remains a key unresolved issue how their formation is mechanistically linked to 
cell death and other pathological events that account for the clinical phenotypes 
(Castellani 1998, Komori 1999, Tran and Miller 1999). Research has been hampered by 
the complexity of the systems involved and the lack of good experimental models. 
However, a range of hypotheses have been put forward, mostly falling into four main 
views where inclusions are either regarded as 1) noxious to the cell, 2) an 
epiphenomenon, 3) structures that sequester toxic proteins, or 4) centers for the 
proteasomal and/or autophagic clearance of aggregated proteins. Selected evidence in 
support of each concept is presented below. 
Inclusions have been proposed to be noxious as such, thereby promoting cell death or 
dysfunction (Trojanowski et al. 1998, Galvin et al. 2001). In addition to direct 
mechanical derangement of cellular structures by voluminous inclusions, noxiousness 
might result if the deposited proteins interfere with cellular processes, e.g. via blockage 
of intracellular transport (Cleveland 1996, Katsuse et al. 2003) or saturation of 
proteolytic capacity (Bence et al. 2001, Keck et al. 2003, Snyder et al. 2003). Detrimental 
effects may also be due to the entrapment of vital signaling intermediates or other 
cellular constituents within the inclusion (Steffan et al. 2000, Nucifora et al. 2001, 
Donaldson et al. 2003, Qin et al. 2004). Neuropathological evidence in support of this 
view encompasses the observed associations of inclusions with cell loss and clinical 
phenotypes, as stated above. Genetic studies have also provided important evidence for 
the primacy of inclusion constituents in the etiopathology of NDs, revealing that certain 
genes which, when mutated, underlie inheritable forms of these diseases (i.e., tau, αS, 
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neuroserpin) encode proteins that represent the major components of the respective 
inclusion types (Polymeropoulos et al. 1997, Hutton et al. 1998, Davis et al. 1999). 
Consistent findings come from rodent models, in which the overexpression of these 
genes may be sufficient to cause phenotypes recapitulating many of the pathological 
features of the human diseases (Lewis et al. 2000, Kirik et al. 2002). Finally, numerous in 
vitro studies have shown that aggregated proteins mimicking those in vivo can cause a 
multitude of adverse effects on cellular function, such as vesicle permeabilization (Volles 
et al. 2001), Golgi fragmentation (Gosavi et al. 2002), microtubule disassembly (Alonso 
et al. 1996), neuritic degeneration (Li et al. 2001), generation of reactive oxygen species 
(Turnbull et al. 2001), cytotoxicity (Bodles et al. 2000, Yang et al. 2002), and apoptotic 
cell death (El-Agnaf et al. 1998, Kouroku et al. 2000). 
According to a contrary view, inclusion formation might represent an epiphenomenon 
not influencing the pathological processes that cause cell death. In favor of this view, the 
severity of neuronal death often seems disproportionately high in comparison with the 
frequency of inclusions in the same brain area (Terry 2000). Vice versa, individual cases 
may display exceptionally high densities of inclusions in brain regions with no sign of 
cell loss (van Duinen et al. 1999). Similarly, in some animal models, inclusion formation 
is not accompanied by cell death (Auluck et al. 2002, Lo Bianco et al. 2002). Further, 
inclusion-bearing cells appear to remain viable, even for years (Hatanpää et al. 1996, 
Tompkins and Hill 1997, Morsch et al. 1999). 
A view that may better explain the empirical findings is the scenario that inclusions as 
such may only exert a minor adverse effect on the host cell, while serving as structures 
which sequester aberrant proteins that otherwise would be noxious (Iqbal et al. 1998, 
Denk et al. 2000, Volles and Lansbury 2003). Evidence from cell-free systems, in 
particular, suggests that the sequestration of such proteins into inclusions may play an 
adaptive role, by promoting the elimination of toxic prefibrillar intermediates, 
“protofibrils”, favoring their conversion into a more inert, fibrillar form (Bucciantini et 
al. 2002, Lashuel et al. 2002a, Caughey and Lansbury 2003). Supportive evidence comes 
from human postmortem studies that sometimes reveal inverse correlations between 
inclusion abundance and cell loss (Kuemmerle et al. 1999, Takahashi et al. 2001), 
suggesting that cells capable of forming inclusions might be more resistant against 
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aberrant proteins. Consistently, some early-onset types of NDs display no inclusions 
characteristic of the late-onset phenotype (Mizuno et al. 2001), suggesting that the 
inability to form inclusions might lead to accelerated pathogenesis. Along similar lines, 
experiments with genetically modified mice suggest that inclusion formation renders 
cells less vulnerable to aggregation-prone proteins and other insults (Cummings et al. 
1999, Denk et al. 2000). This conclusion is in accordance with cell culture studies 
showing a dissociation between the processes of inclusion formation and cell death 
(Lang-Rollin et al. 2003, Tanaka et al. 2004). 
A question linked to the pathogenetic significance of inclusions concerns the nature of 
the process whereby they are formed: it is unclear to what extent inclusions emerge as a 
result of unregulated events, and to what extent their formation may be governed by 
regulatory systems (Taylor et al. 2002). The view of inclusion formation as a haphazard 
phenomenon, driven by aberrant intermolecular interactions, is apparently favored by the 
varied morphologies of different inclusions and their heterogenous compositions. In 
addition, some features of disease-associated inclusions, such as fibrillization, can be 
reproduced in cell-free conditions (Conway et al. 1998, Barghorn and Mandelkow 2002), 
pointing to the contribution of unregulated events. However, these findings do not 
preclude the involvement of regulatory mechanisms, particularly in the events whereby 
aberrant proteins (fibrillar or not) conjoin into larger focal assemblies. Indeed, evidence 
accumulating from cell culture models suggests that cytoplasmic inclusions are formed in 
a highly regulated manner, via the aggresomal response (Kopito 2000, Garcia-Mata et al. 
2002). In this mechanism, misfolded proteins are transported along microtubuli to the 
pericentriolar area, where they form a condensed mass encaged by intermediate filaments 
(Johnston et al. 1998, Garcia-Mata et al. 1999). Aggresomes may represent a general 
adaptive response in conditions where misfolded or aggregation-prone proteins are 
produced faster than can be eliminated via refolding or degradation (Kopito and Sitia 
2000, Garcia-Mata et al. 2002). This process seems to be cytoprotective when toxic 
proteins accumulate (Taylor et al. 2003, Tanaka et al. 2004). Since aggresomes are 
enriched in components of the Ub-proteasome system and heat shock proteins, they are 
thought to serve as sites of active proteolysis (Wigley et al. 1999). In addition, 
aggresomes seem to facilitate the clearance of aggregated proteins via autophagy 
(Ravikumar et al. 2002, Fortun et al. 2003, Taylor et al. 2003). The aggresomal response 
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has gained increasing recognition as a mechanism potentially underlying the formation of 
neuropathological cytoplasmic inclusions, but it should be noted that as yet there is little 
direct evidence in support of this view. 
2.2 Tau-containing inclusions 
Tau is a microtubule-binding protein that is abundant in the central nervous system 
(CNS), localizing mainly into axons where it stabilizes microtubules (MTs) and promotes 
their polymerization. In the CNS, tau is expressed as 6 splicing isoforms of 352−441 
residues. Tau is a natively unfolded protein with little secondary structure. Functionally, 
the protein is divided into an N-terminal projection domain and a C-terminal MT-binding 
domain, the latter part containing 3 or 4 MT-binding repeats. The sequence also harbors 
numerous phosphorylation sites (Buee et al. 2000, Friedhoff et al. 2000, Lee et al. 
2001b). 
A growing number of tau-immunoreactive neuronal or glial inclusion types have been 
described in a variety of conditions (Feany and Dickson 1996, Esiri et al. 1997, Komori 
1999). Some of the most widely recognized types, each of which is generally believed to 
contain the tau protein as the major constituent, are introduced below. Additional or 
variant types include those presenting in hereditary tau-linked degenerations (Spillantini 
et al. 1998a) and those incorporating tau as a minor or incidental component. 
2.2.1 Neuronal types 
Neurofibrillary tangles The most common type of disease-associated inclusion in the 
brain is the “neurofibrillary tangle” (NFT), one of the neuropathological hallmarks of AD 
(Esiri et al. 1997, Terry et al. 1999). Histologically, NFTs are clearly visualized by silver 
impregnation or amyloid stains. In AD brains, NFTs appear as flame-shaped or globoid 
masses of fibrous intraneuronal material, the morphology depending on the neuronal type 
and the developmental stage of the tangle. Ultrastructurally, NFTs mainly consist of 
dense bundles of paired helical filaments (PHFs) 8−20 nm across (Lee et al. 2001b). 
PHFs may be associated with straight filaments (SFs) and more complex types of fibrillar 
structures (Itoh et al. 1997b, Gomez-Ramos and Moran 1998). The principal constituent 
of PHFs is the tau protein in its hyperphosphorylated forms (HP-tau) (Goedert et al. 
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1995, Iqbal et al. 1998). Immunohistochemistry also reveals the variable incorporation of 
ubiquitin (Ub) (e.g., Bancher et al. 1989a) and a range of other proteins into NFTs (Terry 
et al. 1999). 
In AD brains, NFTs occur in the cerebral cortex and in several subcortical regions (Braak 
and Braak 1991, Terry et al. 1999). Within cortical areas, the distribution of NFTs 
suggests a hierarchical progression that first involves the transentorhinal cortex, from 
where the pathology spreads via limbic areas to the isocortex (Braak and Braak 1991). 
The correlation between the NFT distribution and the severity of clinical expression 
underlies the use of NFTs as markers in the neuropathological diagnosis of AD (NIA-RI 
Working Group 1997). In the neocortex, NFTs mostly appear in large pyramidal neurons 
within layers II−III and V, where they are usually accompanied by abnormal neuronal 
processes, i.e., neuropil threads (NTs) and dystrophic neurites, the latter surrounding 
deposits of β-amyloid. Both types of aberrant neurites contain PHFs and immunolabel for 
HP-tau and Ub (Esiri et al. 1997). In addition to AD, NFTs occur in other tauopathies 
including progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), 
with disease-specific differences in their distribution, structure, and biochemical 
properties (Esiri et al. 1997, Jellinger and Bancher 1998, Vogelsberg-Ragaglia et al. 
1999, Buee et al. 2000). Frequently, brains from neurologically normal elderly 
individuals also show a degree of NFT pathology within limbic areas (Braak and Braak 
1995). 
Pick bodies The “Pick body” (PiB) is characteristic of Pick disease (PiD) (Esiri et al. 
1997, Dickson 1998). Silver impregnation reveals PiBs as intensely argyrophilic, 
rounded to irregular, well-circumscribed inclusions 10−15 µm across. 
Immunohistochemistry shows the presence of HP-tau, variably accompanied by Ub, 
phosphorylated neurofilaments, and other proteins. Ultrastructurally, PiBs contain 
randomly arranged SFs ~15 nm in diameter, admixed with granular constituents, twisted 
filaments dissimilar from AD-type PHFs, and cytoplasmic organelles. Biochemically, the 
filamentous components consist of HP-tau which differs from that found in AD (Buee et 
al. 2000). PiBs are relatively specific for PiD (Feany and Dickson 1996) and have been 
regarded as its defining histopathological feature (Dickson 1998). In affected brains, PiBs 
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are found in the cerebral cortex and in subcortical areas including many brainstem nuclei 
(Yoshimura 1989, Dickson 1998). In the neocortex, PiBs preferentially populate layers II 
and VI (Hof et al. 1994). 
Argyrophilic grains Small HP-tau-immunoreactive inclusions scattered in the neuropil 
constitute the pathological hallmark of argyrophilic grain disease (AGD) (Jellinger 
1998). Best visualized by silver impregnation, “argyrophilic grains” (AGs) appear as 
minute, spindle- or comma-like structures with small protrusions, mostly occurring in the 
hippocampus and nearby limbic areas. In addition to pure AGD, AGs frequently 
accompany other neurodegenerative conditions (Jellinger 1998). AGs reside within 
dendrites, often arranged in short rows and frequently surrounding neurons diffusely 
positive for HP-tau. AGs selectively incorporate the tau isoform with 4 MT-binding 
repeats (Togo et al. 2002). They also label variably for Ub (Ikeda et al. 1995a) and 
engage several tau-phosphorylating kinases (Ferrer et al. 2003). The structural elements 
of AGs appear as accumulations of 9−18-nm SFs or 25-nm smooth tubules (Jellinger 
1998). The formation of AGs is mostly unclear, but the morphology of AG-bearing 
neurons is suggestive of ongoing dendritic shrinkage (Tolnay et al. 1998). 
2.2.2 Glial types 
Coiled bodies Several tauopathies display “coiled bodies” (CBs) in oligodendrocytes. 
CBs occur most numerously in CBD, but are also abundant in PSP and AGD and are less 
common in PiD (Komori 1999). Histologically, CBs are readily detected by Gallyas-
Braak silver impregnation. They may exhibit varied morphologies including coil- or 
comma-like or spine-like with branches, different forms predominating in each disease. 
In CBD, the inclusions usually appear as a bundle of fibrils that coil around an enlarged 
nucleus and extend into proximal processes (Dickson et al. 2002). CBs are 
immunoreactive for HP-tau but generally negative for Ub (Feany et al. 1996, Komori 
1999). Ultrastructurally, their constituents have been described as filamentous or tubular, 
straight or helical structures 9−25 nm in diameter, this variability likely reflecting 
disease-specific differences. CBs may populate regions of the cerebral cortex, basal 
ganglia, brainstem, and cerebellum, with disease-dependent but overlapping 
distributions. The occurrence of CBs is paralleled by that of thread-like tau-
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immunoreactive structures which localize into the myelin-forming processes of 
oligodendrocytes (Komori 1999). The ultrastructural similarity of these thread-like 
structures and CBs suggests that they have an interlinked origin (Arima et al. 1997). 
Astrocytic inclusions Several types of tau deposition within astrocytes occur in various 
conditions, most abundantly in CBD, PSP, and PiD (Chin and Goldman 1996, Komori 
1999). These accumulations, named by their conspicuous features as visualized by the 
Gallyas-Braak technique or HP-tau immunolabeling, include tufted astrocytes, astrocytic 
plaques, as well as thorn-shaped and ramified astrocytes. Each type shows a different 
pattern of disease association(s) and disease-dependent intrabrain distribution(s), and 
may vary somewhat in appearance from disease to disease. This morphological diversity 
may reflect differing populations of affected cells and/or more subtle heterogeneity in the 
underlying pathological processes (Chin and Goldman 1996, Komori 1999). Compared 
to tau inclusions with a compact consistency (e.g., NFTs), those in astrocytes generally 
appear to be less condense, being poorly discernible with conventional silver stains and 
showing few or no fibrillar constituents in ultrastructure, thus resembling the “pre-
tangles” seen in AD (Ikeda et al. 1998). 
“Tufted astrocytes” (TAs) are characteristic of PSP (Komori et al. 1998, Matsusaka et al. 
1998). They are seen as focal aggregates of fine or thick radiating processes in a 
concentric, tuft-like arrangement, often obscuring the nucleus. “Astrocytic plaques” are 
relatively specific to CBD (Ikeda et al. 1998, Dickson et al. 2002). They are reminiscent 
of neuritic plaques in AD but devoid of β-amyloid, appearing as a corona-like 
arrangement of tau-positive, stubby distal processes around an unstained area. Both TAs 
and astrocytic plaques are mostly confined to the gray matter, populating regions of the 
cerebral cortex, basal ganglia, and brainstem. “Ramified astrocytes” are associated with 
PiD. They resemble TAs but appear as a more diffuse form of accumulation that occupies 
more of the cell body and processes (Komori 1999). The biogenesis of these disease-
associated types of astroglial inclusions is poorly understood, but at least in the case of 
TAs, tau accumulation seems to be a degenerative rather than a gliosis-related process 
(Togo and Dickson 2002). Unlike the above types, “thorn-shaped astrocytes” show no 
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overt disease specificity. Their occurrence is mostly limited to subpial and subependymal 
areas and may be promoted by gliosis (Ikeda et al. 1995b). 
2.2.3 Formation of AD-type neurofibrillary tangles 
A variety of empirical approaches have been employed to elucidate the formation of tau-
containing inclusions, utilizing either human postmortem tissues or diverse experimental 
models ranging from non-human primates to cell-free systems. In human tissues, the 
inclusion type most extensively studied is the AD-type NFT which will be the main focus 
here. However, much of the insight obtained from various models of human tauopathies 
is not specific to any particular disease but rather may apply to other types of tau 
inclusions besides or instead of those in AD. 
Neuropathological findings While only a limited amount of mechanistic insight can be 
extracted from studies on human autopsy-derived brain material, it has been possible to 
shed light on the events underlying NFT formation by reconstructing a morphological 
description of the process. To this end, tau accumulations in affected brain regions of 
cases with various extents of AD-type pathology have been visualized using immuno-
histochemical and other stains. By tentative ordering of the structures thus observed, the 
most likely sequence of events has been inferred, largely on morphological grounds 
(Bancher et al. 1989a, Braak et al. 1994, Sassin et al. 2000, Uboga and Price 2000, 
Lauckner et al. 2003). Additional clues into the underlying events have been obtained 
from human tissues by determining the identities, modifications, and ultrastructure of 
NFT constituents using immunohistochemistry, biochemical analyses, and electron 
microscopy. 
The distinction of early, mature, and end stage forms of NFTs was already suggested by 
Alois Alzheimer (see Bancher et al. 1989a). Thereafter, the morphogenesis of NFTs has 
been characterized in the greatest detail in pyramidal neurons of layer Pre-α of the 
entorhinal/transentorhinal region (Braak et al. 1994) and in large neurons of the basal 
nucleus of Meynert (Sassin et al. 2000). The antibody AT8 that recognizes a 
phosphoepitope in early pathological tau (Su et al. 1994) and Gallyas silver impregnation 
were used to visualize earlier and later stages of neurofibrillary changes, respectively. 
The overall sequence of events was similar in the two regions, with the minor 
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dissimilarities likely attributable to differences in the structures of the afflicted neurons. 
As proposed by the authors, tau accumulation first appears as even, granular, or hatched 
AT8-immunoreactivity throughout the perikaryon and processes of an otherwise normal-
looking neuron. The second stage is the appearance within the perikaryon of small 
filamentous or rod-like inclusions (early tangle) that often colocalize with lipofuscin. 
Concomitantly, axonal AT8-positivity is lost, and deterioration of dendrites begins, first 
evident in distal parts as conspicuous changes such as fragmentation, thickening, 
decrease of AT8-immunoreactivity, and the appearance of tortuous or rod-like portions 
and terminal swellings. Argyrophilia also emerges, silver impregnation revealing singular 
filamentous inclusions in the soma and distal neuritic fragments. The following stage 
represents the classic NFT, shown by both stains as a globular or flame-like mass of 
bundled filaments that partially displace the nucleus. Dendrites undergo further 
degeneration, losing much of their AT8-positivity, while tortuous fragments may remain 
around the soma. The final stages entail the death of the neuron as evident from the 
disappearance of the cell body. The NFT remains as a “ghost” tangle, which gradually 
loses its AT8-immunoreactivity but retains argyrophilia as a loosely packed filamentous 
mass (Braak et al. 1994, Sassin et al. 2000). The ghost tangles become infiltrated by 
processes of glial fibrillary acidic protein (GFAP)-positive astrocytes and by activated 
microglia (Probst et al. 1982, Cras et al. 1991, Sheng et al. 1997). 
Similar morphogenetic schemes, i.e., a progression from a “pre-tangle” stage (diffuse or 
granular cytoplasmic staining for tau/HP-tau) via classic NFT to an extracellular tangle, 
have been derived by other authors (Bancher et al. 1989a, Lauckner et al. 2003). The 
transition from the pre-tangle stage to classic NFT seems to involve a conformational 
change in tau (Uboga and Price 2000) and progressive phosphorylation at specific sites 
(Kimura et al. 1996, Augustinack et al. 2002, Lauckner et al. 2003), as shown using 
conformation- and phosphoepitope-dependent antibodies. Compared with tau, Ub 
immunoreactivity appears late in the process of NFT formation, following argyrophilia 
and persisting in ghost tangles (Bancher et al. 1989a, Bancher et al. 1991, Uchihara et al. 
2001). 
Ultrastructural studies suggest that the transition from pre-tangle to NFT is accompanied 
by the conversion of nonfilamentous or granular tau into fibrillar form (Bancher et al. 
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1989a, Weaver et al. 2000). In the pre-tangle neuron, AT8 immunoreactivity is mostly 
present diffusely in the cytoplasm, with focal concentrations that seem to be the initial 
site of fibrillogenesis. Progressive incorporation of the diffuse material into PHFs and 
SFs coincides with the emergence of an early NFT. Upon tangle maturation, the fibrils 
aggregate and align into densely packed bundles that contain PHFs peripherally and SFs 
in the core, finally filling most of the perikaryon as a classic NFT (Gomez-Ramos and 
Moran 1998). 
Despite the consensus on the morphogenetic events in NFT life span, little is known on 
the duration of each developmental stage. However, mathematical modeling, based on 
quantified neuronal loss and NFT abundance in AD hippocampus, suggests that neurons 
might survive with NFT for 15−25 years (Morsch et al. 1999). A long lifetime for NFT-
bearing neurons is also supported by stereological analyses in limbic and neocortical 
areas of AD brains (Bussiere et al. 2003, Hof et al. 2003). Consistent with these findings, 
direct measurement of neuronal activity using metabolic markers showed that NFT-
bearing neurons remain active, albeit at a lower metabolic level compared to normal 
neurons (Hatanpää et al. 1996). 
In addition to tau and Ub, an increasing number of proteins or other biomolecules have 
been localized into NFTs. Some of these also accumulate in pre-tangle neurons, possibly 
suggesting an early involvement in neurofibrillary changes. The latter constituents 
include the cdk5 protein kinase (Pei et al. 1998) and active forms of cdc2, MEK1/2, 
ERK1/2, and GSK-3β (Pei et al. 1999, Ferrer et al. 2001, Pei et al. 2002a, Pei et al. 
2002b), translation initiation factor 2α (Ferrer 2002), several septins (i.e., cytoskeletal 
GTPases) (Kinoshita et al. 1998), active calpain II (Grynspan et al. 1997), and sulphated 
glycosaminoglycans (sGAGs) (Goedert et al. 1996). The potential significance of these 
and other NFT constituents for tau fibrillization and tangle formation remains to be 
elucidated, but mechanistic studies suggest promoting roles for most of the above kinases 
as well as for calpains and sGAGs. 
The total amount of tau is 4−8-fold elevated in AD, resulting from the accumulation of 
hyperphosphorylated tau (Khatoon et al. 1992, Khatoon et al. 1994). Besides hyper-
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phosphorylation, a variety of other modifications in tau have been identified in AD, as 
shown by immunolocalization into NFTs and/or by biochemical analysis of brain-
extracted pathological tau. These modifications include glycation, N- and O-linked 
glycosylation, oxidation, nitration, truncation, ubiquitination, and transglutaminase-
catalyzed cross-linking (Norlund et al. 1999, Buee et al. 2000, Gamblin et al. 2003, 
Horiguchi et al. 2003), but quantitative data on the extents of each in different stages of 
tangle formation is mostly lacking. Finally, while PHFs contain the 6 isoforms of tau in 
proportions similar to normal tau (Goedert et al. 1995), the isoform composition and 
morphology of PHFs vary in different neuronal compartments (Liu et al. 1993, Kurt et al. 
1997, Ishizawa et al. 2000). As in the case of the other constituents of NFTs, it is mostly 
unclear to what degree and how the alterations of tau structure or isoform ratios might 
contribute to tau aggregation into NFTs. 
Mechanistic aspects Based on the morphogenetic descriptions of tau aggregation into 
NFTs (Braak et al. 1994, Gomez-Ramos and Moran 1998), the process can be viewed as 
three partially overlapping subprocesses: 1) accumulation of nonfibrillar tau throughout 
the cytoplasm of an initially normal neuron, 2) conversion of cytoplasmic, nonfibrillar 
tau into PHFs and other filamentous forms, and 3) bundling of separate fibrils into a large 
NFT. At the molecular level, each subprocess is poorly understood due to the scarcity of 
good experimental models, but studies on human material and available models have 
provided variable degrees of evidence for possible mechanisms. 
While the changes that precede and expedite tau pathology in AD brains likely involve 
altered metabolism of amyloid precursor protein (Lewis et al. 2001, Delacourte et al. 
2002, Hardy and Selkoe 2002), the immediate events leading to the accumulation of 
nonfibrillar (HP-)tau remain unclear. It is well established that AD-like 
hyperphosphorylation of tau may cause its detachment from MTs (Biernat et al. 1993, 
Bramblett et al. 1993, Friedhoff et al. 2000) and sequestration of normal tau (Alonso et 
al. 1994, Alonso et al. 1996, Iqbal et al. 1998), possibly underlying the somatodendritic 
accumulation of tau. Consistently, after genetic manipulations that increase tau 
phosphorylation, an elevation of unbound HP-tau is seen in cultured cells (e.g., Xie et al. 
1998, Hamdane et al. 2003) and somatodendritic HP-tau emerges in mice (Kins et al. 
2001, Lucas et al. 2001, Liou et al. 2003). However, the dissociation of tau from MTs 
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may also be promoted by other factors such as sGAGs (Hasegawa et al. 1997). On the 
other hand, the several-fold increase of total tau in AD (Khatoon et al. 1994) implies that 
there is a disturbance of tau synthesis and/or degradation. Indeed, the expression of tau 
mRNA is increased in affected brain areas (Barton et al. 1990), possibly with a shift in 
the isoform ratios towards 4-repeat tau (Yasojima et al. 1999), and in mice, 
overexpression of normal tau leads to pre-tangle-like accumulation (Götz et al. 1995, 
Brion et al. 1999). Tau may also fail to be properly degraded due to modifications that 
render it refractory to proteolysis (Litersky and Johnson 1995, Yang and Ksiezak-Reding 
1995) and/or due to a decline in proteasome activity as seen in AD (Keller et al. 2000, 
Keck et al. 2003). One possible cause for this decline might be the accumulation of 
frameshift mutant Ub (van Leeuwen et al. 1998) which inhibits the Ub-proteasome 
system in vitro (Lindsten et al. 2002, Hope et al. 2003). 
Elucidation of the structural basis of tau fibrillization has been hampered, since the 
natively unfolded character of soluble tau has prevented its structural determination 
(Barghorn and Mandelkow 2002) and the fine structure of PHFs also remains debatable 
(Pollanen et al. 1997, Moreno-Herrero et al. 2004). In addition, attempts to produce tau 
fibrils in cultured cells have been frustrated by the hydrophilicity of tau (Friedhoff et al. 
2000). Therefore, insight into fibril formation mostly comes from cell-free experiments, 
where a variety of conditions have been employed to induce fibril assembly from 
recombinant tau proteins (Barghorn and Mandelkow 2002). These studies show that 
fibrils with various morphologies, some indistinguishable from PHFs in AD, can 
assemble from unmodified tau isoforms over a time scale of days to weeks (Goedert et al. 
1996, Perez et al. 1996, Friedhoff et al. 1998, King et al. 1999), while only the MT-
binding repeat regions seem to be crucial for fibrillization (Kampers et al. 1996, Perez et 
al. 1996). The process is nucleation-dependent and can be greatly accelerated in the 
presence of cofactors such as polyanions (i.e., sGAGs, RNA, and polyglutamate) 
(Goedert et al. 1996, Friedhoff et al. 1998) or fatty acids (Wilson and Binder 1997), 
which may balance the positive charges present in tau. 
Findings from two well-characterized systems (Friedhoff et al. 1998, King et al. 1999) 
were compatible with a structural model in which the basic building block of fibril 
assembly is a dimer of antiparallel tau molecules that interact via their repeat regions. 
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Fibrils would result from stacking of such dimers, involving a conformational change 
and, in oxidative conditions, stabilization by disulfide bridges (Barghorn and Mandelkow 
2002). Consistent with this model, PHFs in AD contain a protease-resistant core formed 
by the repeat regions in a cross-β arrangement (Novak et al. 1993, Barghorn et al. 2004). 
Although the conditions in cell-free systems differ in numerous ways from those in vivo, 
the findings suggest that also in AD, tau fibrillization might be promoted by cofactors 
such as RNA (Ginsberg et al. 1997) and sGAGs (Goedert et al. 1996), by oxidative stress 
(Markesbery 1999), or by accumulation of tau even in the absence of cofactors or 
modifications. 
The role of phosphorylation in tau fibrillization is unclear. In the presence of polyanions, 
the phosphorylation of tau by several different kinases inhibited its assembly into fibrils 
(Schneider et al. 1999). However, in more physiological conditions utilizing no cofactors, 
heavy hyperphosphorylation of tau by brain extracts induced a rapid formation of PHFs 
and SFs which further associated into bundles (Alonso et al. 2001). This apparent 
disparity may suggest that the effect on fibrillization is determined by the sites and extent 
of phosphorylation. 
Few studies have addressed the molecular events whereby separate fibrils conjoin into a 
large NFT. While spontaneous bundling occurs in some models (Alonso et al. 2001), this 
process may be promoted by glycation (Ledesma et al. 1998), which is seen in PHF 
bundles in AD (Ko et al. 1999). The bundling of fibrils seems to precede the emergence 
of Ub immunoreactivity (Iwatsubo et al. 1992), an event of unclear significance. The 
incorporation of Ub might reflect a malfunction of Ub-dependent proteolysis in affected 
neurons (Alves-Rodrigues et al. 1998), which might result from the inhibition of 
proteasomes by fibrillar tau (Keck et al. 2003), causing the general buildup of Ub-
conjugated proteins. Alternatively, the late-emerging Ub-positivity in NFTs might arise 
from the ubiquitination of tangle constituents as part of an adaptive cellular response. For 
example, it might indicate an attempt at proteasomal degradation (Layfield et al. 2003), 
as evidenced by the presence of some proteasomal subunits in NFTs (Fergusson et al. 
1996). However, it should be noted that most of the Ub conjugated to PHFs seems to 
occur in the monomeric form (Morishima-Kawashima et al. 1993), a poor signal for 
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efficient proteasomal targeting (Thrower et al. 2000), while in vitro, tau can undergo 
proteasomal degradation without any requirement for ubiquitination (David et al. 2002). 
Therefore, pathways for Ub conjugation might also be defective in tangle-bearing 
neurons. Another suggestion, based on the localization of the Ub-conjugation sites in the 
MT-binding region of tau, is that the core of PHFs could be highly refractory to 
proteasomal digestion (Morishima-Kawashima et al. 1993). One further possibility, 
proposed by Gray (2001), is that the (mono)ubiquitination of PHFs might serve a non-
proteolytic role as a “nonstick coating” that would prevent the further growth of the 
aggregates and limit detrimental interactions with normal cellular constituents. However, 
there is currently little direct evidence in support of any of the above hypotheses. 
2.3 α-Synuclein-containing inclusions 
α-Synuclein is an abundant presynaptic protein that in the brain is expressed mostly as an 
isoform of 140 residues (Goedert 2001, Lotharius and Brundin 2002, Dev et al. 2003). It 
is located mainly in nerve terminals, where it is found in close proximity to synaptic 
vesicles, both membrane-associated and free in the cytosol. The functions of αS are not 
well established, but its key function is thought to be in the regulation of synaptic 
vesicular transport, including that of dopamine, possibly via inhibition of phospholipase 
D2. Other aspects of dopamine metabolism may also be regulated by αS. Similar to tau, 
αS is a natively unfolded protein. It comprises an N-terminal domain harboring 11-amino 
acid repeats that bind to membranes by assuming an α-helical structure, a hydrophobic 
intermediate region, and a C-terminal acidic region with chaperone-like activity. A 
number of proteins and other ligands including fatty acids interact directly with αS 
(Goedert 2001, Lotharius and Brundin 2002, Dev et al. 2003). 
Several pathological conditions are associated with the formation of cytoplasmic 
inclusions that assumably contain αS as their main protein component (Galvin et al. 
2001). The most common types of these are described below. 
2.3.1 Neuronal types 
Lewy bodies The most common type of αS-containing inclusion is the “Lewy body” 
(LB), which are usually classified into brainstem and cortical types (Gibb et al. 1991, 
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Forno 1996, Lowe et al. 1997). In the brainstem, “classic” LBs appear within neuronal 
perikarya as eosinophilic, conspicuously spherical inclusions with a concentric 
lamination (core, body, and halo), although not all layers are usually discernible. 
Ultrastructurally, the core is densely granular, while the outer layers contain haphazardly 
to radially arranged filaments. Cortical LBs usually display a less rounded and more 
uniform morphology. Both brainstem and cortical LBs are assumed to be mainly 
composed of aberrant αS fibrils, 5−10 nm in diameter (Baba et al. 1998, Spillantini et al. 
1998b, Goedert 2001). Immunohistochemistry shows a less consistent incorporation of 
numerous other proteins (Dev et al. 2003) including polyubiquitinated species (Iwatsubo 
et al. 1996) and phosphorylated neurofilaments (Bancher et al. 1989b). 
LBs may occur in various predilection sites of the brain as well as in sympathetic ganglia 
(Pollanen et al. 1993), showing variable distributions which often associate with clinical 
states that reflect the pattern of involvement (Lowe et al. 1997). In particular, the 
presence of LBs in the substantia nigra (SN) and other pigmented brainstem nuclei is a 
diagnostic hallmark of PD (Forno 1996), whereas their occurrence in the cerebral cortex 
is used as a criterion for the diagnosis of dementia with LBs (DLB) (McKeith et al. 
1996). However, “incidental” LBs also occur in neurologically normal aged individuals. 
Perikaryal LBs are usually accompanied by thread-like or swollen αS-immunoreactive 
neurites, as well as by globular αS-immunoreactive inclusions within neuronal processes 
or apparently free-lying in the neuropil (Spillantini et al. 1998b). These extrasomal 
inclusions are also commonly referred to as LBs, despite their somewhat differing 
morphology as compared to the perikaryal ones. 
Pale bodies Another type of PD-associated inclusion is the “pale body” (PaB). These are 
weakly or non-eosinophilic, globular or irregular bodies of homogenous or uniformly 
granular material that seems to displace neuromelanin but fails to stain with many 
common histological stains or silver impregnation (Roy and Wolman 1969, Pappolla et 
al. 1988, Gibb et al. 1991). However, they are slightly reactive with the Ninhydrin-
periodic acid-Schiff method, indicating a low protein content (Pappolla et al. 1988). 
Ultrastructurally, PaBs consist of disorganized, αS-immunoreactive fibrils interspersed 
with vacuoles and granular matter (Gibb et al. 1991, Arima et al. 1998b, Wakabayashi et 
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al. 1998a). Besides moderate to strong immunoreactivity for αS, most PaBs stain 
variably for Ub, a minority also for phosphorylated neurofilaments (Dale et al. 1992). 
PaBs have been found in neurons of the SN and locus coeruleus, but not in several other 
predilection areas for LB pathology (Gibb et al. 1991). The pathogenetic relation of PaBs 
and LBs remains unclear. Although PaBs seem to occur in the SN of all PD patients 
(Pappolla et al. 1988), they are generally not used for diagnosis. 
2.3.2 Glial types 
Glial cytoplasmic inclusions The defining feature of multiple system atrophy (MSA) is 
the presence of “glial cytoplasmic inclusions” (GCIs) within oligodendrocytes (Castellani 
1998, Gilman et al. 1999). GCIs are faintly eosinophilic, sickle- or flame-shaped or ovoid 
inclusions that seem to displace the nucleus. They can be visualized with the Gallyas 
silver technique but are mostly negative for other histological stains. Similar to LBs, 
GCIs immunostain strongly for αS (e.g., Wakabayashi et al. 1998b). Ultrastructurally, 
GCIs contain loosely aggregated αS-immunoreactive tubules or filaments, 20−40 nm 
across, associated with granular material and organelles (Arima et al. 1998a, 
Wakabayashi et al. 1998a, Burn and Jaros 2001). A detailed study on immunoisolated 
GCIs revealed bundles of amorphous material-coated filaments, the core of which 
consisted of paired strings of 3−6 nm particles, possibly representing αS oligomers (Gai 
et al. 2003). Biochemical analysis identified Ub, αB crystallin, and tubulins as additional 
constituents (Gai et al. 1999), while other proteins were variably present as determined 
by immunolabeling (Castellani 1998, Burn and Jaros 2001). 
In MSA brains, GCIs are widely distributed (Papp and Lantos 1994, Inoue et al. 1997) 
and represent the predominant inclusion type. They may be accompanied by inclusions in 
neurons and in glial and neuronal nuclei, as well as by neuropil threads (Lowe et al. 
1997). Apart from glial nuclear inclusions, each structure immunolabels positively for αS 
(Wakabayashi et al. 1998a). The mechanisms underlying the formation of GCIs as well 
as their pathogenetic significance remain mostly unknown. However, biochemical 
analyses of MSA brain specimens indicate that the conversion of αS to poorly soluble 
forms may contribute to GCI formation (Tu et al. 1998, Dickson et al. 1999, Duda et al. 
2000, Campbell et al. 2001), while immunohistochemical evidence points to the 
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involvement of αS phosphorylation (Fujiwara et al. 2002) and nitration (Giasson et al. 
2000) in the pathogenesis of synucleinopathies including MSA. 
2.3.3 Formation of brainstem-type Lewy bodies 
Compared to AD-type NFTs, the formation of LBs is less well characterized and 
understood since their assumed main component, αS, was not identified until 1997 
(Polymeropoulos et al. 1997, Spillantini et al. 1997). On the other hand, a wider range of 
options are available for studying αS aggregation in animal models, where it is possible 
to induce a PD-like phenotype not only by αS overexpression but also pharmacologically 
by several types of compounds. Below, the focus will be on brainstem-type LBs, which 
have been more extensively characterized than the cortical type.  
Neuropathological findings Before the introduction of αS immunolabeling, studies were 
biased towards conspicuous inclusions visualizable using nonspecific stains, therefore 
missing earlier types of pathological change. Among the initial observations on nigral 
inclusions was the distinction of PaBs from LBs by their histological staining properties 
(Redlich 1930) and ultrastructure (Roy and Wolman 1969). These authors’ interpretation 
was that PaBs are an early change in LB development. However, in subsequent studies 
utilizing histological stains, electron microscopy, and immunolabeling for 
neurofilaments, PaBs and LBs were deemed to be not directly related on the basis of their 
dissimilar staining and ultrastructural profiles (Pappolla et al. 1988, Gibb et al. 1991). 
The lack of intermediate forms between PaBs and LBs was also pointed out, whereas a 
more likely precursor of LBs seemed to be a third type of fibrillar accumulation, termed 
as ”Lewy-body-like matter” (Gibb et al. 1991). However, this latter type has not been 
described in other studies. 
On the other hand, the above studies also revealed that PaBs are always accompanied by 
LBs in the SN (Pappolla et al. 1988) and co-occur in the same neuron more often than 
expected by chance (Gibb et al. 1991). These findings implied that the formation of LBs 
and PaBs is closely related, with the possibility that they might be formed as successive 
stages of the same process. Indeed, immunolabeling for Ub had revealed inclusions 
interpreted as intermediary forms of PaBs and LBs (Leigh et al. 1989). Dale et al. (1992) 
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found that PaBs and LBs correlate in abundance, and that PaBs seemed to emerge before 
LBs, but the issue on separate processes vs. successive stages remained unsettled. 
Subsequently, transitional forms between PaBs and LBs were also illustrated 
ultrastructurally in the locus coeruleus (Takahashi et al. 1994), with the suggestion that 
PaBs would give rise to LBs, although only one atypical non-parkinsonian case was 
examined. 
The introduction of αS immunostaining enabled the detection of less conspicuous types 
of αS accumulation, appearing as “diffuse” (Wakabayashi et al. 1998a, Saito et al. 2003) 
or “cloud-like” (Gomez-Tortosa et al. 2000) cytoplasmic αS-positivity in otherwise 
normal-looking neurons, and interpreted as early changes, giving rise to the larger 
inclusions in the SN. In pigmented neurons of lower brain stem nuclei, another subtle 
change was found, i.e., “dust-like” αS particles, but their presence in the SN was not 
examined (Braak et al. 2001). These studies also revealed the αS-positivity of PaBs. 
Ultrastructurally, the αS-positive material in PaBs and LBs appeared to be similar, 
consisting of (granulo-)filamentous components, more densely packed in LBs (Arima et 
al. 1998b, Wakabayashi et al. 1998a), lending support to the view that PaBs are 
precursors to LBs. Thus, Wakabayashi et al. (1998a) suggested a model for the formation 
of nigral LBs, in which αS is initially seen as weak, diffuse cytoplasmic staining, 
followed by the appearance of irregularly shaped accumulations that evolve into clearly 
demarcated inclusions (PaBs) and further to typical LBs. This process seemed to be 
accompanied by progressive loss of neuromelanin and the increase of αS 
immunoreactivity. A consistent scheme was proposed by Gomez-Tortosa et al. (2000), 
with the note that Ub-positivity seemed to be engaged upon the appearance of more 
compact inclusions. Results obtained by immunolabeling for Ser-129-phosphorylated αS 
also conformed to the above model (Saito et al. 2003). Taken together, the consensus 
view is that LB formation begins from a dispersed cytoplasmic accumulation of αS 
(diffuse, cloud-like, or dust-like), from which PaBs and LBs evolve sequentially, but the 
fine structure of the initial change as well as the sequence of intermediate events remain 
to be defined. 
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In addition to the above findings on events confined to neuronal perikarya, studies on the 
overall progression of αS pathology in PD suggest that the emergence of αS-positive 
neurites precedes that of perikaryal inclusions in brainstem nuclei including the SN (Del 
Tredici et al. 2002, Braak et al. 2003). The neurites were presumed to be mostly axonal 
(Braak and Braak 2000). However, it has not been determined how this intraneuritic 
accumulation of αS relates to that within perikarya. 
The pathological αS that accumulates in LB-containing tissues differs from normal αS in 
several ways, as indicated by biochemical and immunohistochemical analyses (Dev et al. 
2003). It is less soluble (Campbell et al. 2000, Kahle et al. 2001), contains partially 
truncated as well as higher molecular weight species of αS (Baba et al. 1998, Tofaris et 
al. 2003), and is mostly phosphorylated at Ser-129 (Fujiwara et al. 2002). The 
pathological αS is also partially conjugated to Ub (with mono- to polyubiquitinated 
species) (Hasegawa et al. 2002, Sampathu et al. 2003) and contains a modified ~23-kD 
form of αS (Tofaris et al. 2003). In addition, pathological αS is nitrated at tyrosine 
residues (Giasson et al. 2000) and is enriched in transglutaminase-catalyzed crosslinks 
(Junn et al. 2003, Andringa et al. 2004). Epitopes for advanced glycation endproducts 
also appear in nigral LBs (Munch et al. 2000). In addition to insoluble αS, PD and DLB 
brains show elevated levels of soluble αS oligomers (Sharon et al. 2003), which seem to 
form in the presence of polyunsaturated fatty acids (Perrin et al. 2001) and were 
suggested by Sharon et al. to precede the aggregation of αS into insoluble forms. The 
significance of these disease-associated alterations in αS for LB formation remains 
unclear. However, in vitro, several of them affect the propensity of αS to undergo 
aggregation (p. 41). 
In addition to αS and Ub, numerous other protein species, as well as lipids, accumulate 
into LBs (e.g., Pollanen et al. 1993, Trimmer et al. 2004). While the protein constituents 
include signaling and cytoskeletal proteins and those involved in cell stress and protein 
degradation and might thus serve causal, structural, or adaptive functions in LB 
formation or only be passively entrapped into the LB (Pollanen et al. 1993), there is 
currently little evidence to assign specific functional roles for most of the identified 
components. In contrast to LBs, few proteins have been reported to localize into PaBs, in 
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accordance with their histological staining properties that suggest a low protein content 
(Pappolla et al. 1988). 
Mechanistic aspects Analogous with the case of NFTs and tau, the events underlying LB 
formation constitute three overlapping subprocesses: 1) accumulation of αS within 
perikarya and neurites, 2) fibrillogenesis from normal αS, and 3) segregation of 
pathological αS into discrete inclusions. Some of the relevant findings providing 
mechanistic insight into these phenomena are compiled below. It should be noted that 
much of the observations from cell culture and cell-free studies may be relevant to αS-
containing inclusions regardless of their type. 
It is unclear whether the perikaryal accumulation of αS results from increased 
expression, impaired degradation, or from a redistribution of αS. Consistent with the 
notion that an elevation of αS mRNA level may promote αS accumulation, a triplication 
of the αS locus was identified in a family with autosomal dominant PD (Singleton et al. 
2003). Likewise, in several mice and primate models, overexpression of normal human 
αS causes diffuse perikaryal accumulation of αS (Kahle et al. 2000, Matsuoka et al. 
2001, Richfield et al. 2002, Kirik et al. 2003). However, in a sample of 9 PD cases, a 
decrease of αS mRNA expression was found in the SN (Neystat et al. 1999), whereas in 
neocortical areas of DLB brains, no change (Wirdefeldt et al. 2001) or an increase 
(Rockenstein et al. 2001) in the αS mRNA level was observed. Although the latter three 
studies reveal no consistent relation to LB pathology, it should be noted that αS mRNA 
levels in tissues with advanced pathology may not reflect the events at earlier stages. 
The accumulation of αS may also stem from impaired proteolysis (McNaught and 
Olanow 2003). Both PD and DLB brains show a loss of proteasomal subunits and 
activity in the SN (McNaught and Jenner 2001, McNaught et al. 2003, Tofaris et al. 
2003), and mutations in two enzymes of the Ub-proteasome pathway cosegregate with 
early-onset PD (Kitada et al. 1998, Leroy et al. 1998). In addition, fibrillization renders 
αS more resistant towards proteinase K digestion (Giasson et al. 2001, Neumann et al. 
2002), while both monomeric and aggregated αS inhibit proteasomal activity (Snyder et 
al. 2003, Lindersson et al. 2004). Although the mechanism of αS degradation is unclear, 
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at least some of the normal αS may be degraded via the proteasome (Bennett et al. 1999, 
Webb et al. 2003), albeit in a Ub-independent manner (Tofaris et al. 2001). Thus, a self-
maintaining cycle may ensue in which proteasomal dysfunction promotes the 
accumulation of αS and vice versa, leading to a buildup of proteasome-dependent 
substrates. Accordingly, drug-induced inhibition of proteasomes in cell culture (Rideout 
et al. 2001, Rideout and Stefanis 2002) and in rat brain (McNaught et al. 2002a, Fornai et 
al. 2003) results in the formation of inclusions, many of which contain αS. On the other 
hand, the data on the proteasomal degradation of αS have been disputed (Ancolio et al. 
2000, Biasini et al. 2004), with other studies pointing to autophagic (Webb et al. 2003) or 
lysosomal (Paxinou et al. 2001, Lee et al. 2004) pathways. Further, the accumulation of 
αS in PD seems to precede that of Ub which is only present in a subset of LBs (Dale et 
al. 1992), a finding corroborated by results from transgenic models (Dev et al. 2003). 
These findings might suggest instead that proteasomal dysfunction may not contribute to 
the early stages of αS accumulation, but becomes manifest later as the incorporation of 
Ub into LBs due to the overload of Ub-dependent degradation pathways (Layfield et al. 
2003). 
The perikaryal accumulation of αS might also be contributed to by a redistribution of the 
normally presynaptic αS into the neuronal bodies, as seemed to occur in an MPTP-
induced primate model (Kowall et al. 2000). In PD, this kind of redistribution might 
ensue from a retardation in axonal transport, as observed for αS in aging mice, also 
providing a possible explanation for the occurrence of the first αS aggregates within 
neurites (Li et al. 2004). Evidence for defective axonal transport was also provided by the 
finding that axonally transported proteins seem to progressively accumulate into 
developing LBs (Katsuse et al. 2003). 
Oxidative stress and mitochondrial defects are implicated in PD pathogenesis (Schapira 
1996, Jenner 2003) and could contribute to the abnormal buildup of αS. Indeed, 
mitochondrial toxins (i.e., MPTP, rotenone, paraquat) caused αS accumulation within the 
perikarya of nigral neurons in both mice (Betarbet et al. 2000, Vila et al. 2000, Manning-
Bog et al. 2002) and the baboon (Kowall et al. 2000), an effect that may be mediated by 
retarded degradation of αS (Sherer et al. 2002) and/or upregulation of αS expression 
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(Vila et al. 2000, Gomez-Santos et al. 2002). Further, spontaneous formation of αS-
containing inclusions that replicated many of the antigenic and structural features of LBs 
occurred in a long-term culture of neuroblastoma cells expressing mitochondrial genes 
from PD patients (Trimmer et al. 2004). Although the underlying events in these models 
are unclear, complex self-maintaining mechanisms may be involved, based on the 
multiple interconnections between oxidative stress, mitochondrial and proteolytic 
dysfunction, and accumulation/aggregation of αS (Lotharius and Brundin 2002, Jenner 
2003). 
As regards the structural basis of αS fibrillization, it may be relevant that αS (Weinreb et 
al. 1996) as well as tau (Schweers et al. 1994) belong to the class of intrinsically 
unstructured (natively unfolded) proteins (IUPs), characterized by extended, flexible, 
random-coil-like conformations with little secondary structure (Tompa 2002). Notably, 
the structural plasticity and other characteristic features of the IUPs that are essential for 
their functions might also favor the formation of pathological fibrils (Uversky and Fink 
2004). In particular, many IUPs, including αS and tau (Syme et al. 2002), show a 
preference for the type II polyproline helical conformation that, while providing 
flexibility for molecular recognition, may also confer a propensity for the conversion to 
β-sheet structure (Tompa 2002). 
Nevertheless, it is poorly understood how the natively unfolded and soluble αS becomes 
arranged into insoluble, ordered fibrils. In concentrated solutions, αS monomers 
spontaneously aggregate within days to months into fibrils similar to those in LBs (e.g., 
Conway et al. 1998, Giasson et al. 1999), although the morphology of the fibrils is highly 
dependent on the assembly conditions (Hoyer et al. 2002). Fibrillogenesis appears to 
occur via oligomeric, metastable intermediates, “protofibrils”, the formation of which 
involves a change from random coil to β-sheet conformation (Conway et al. 2000b, Ding 
et al. 2002, Lashuel et al. 2002b). The protofibrils are heterogenous, including spherical, 
chain-like, and annular types (Volles and Lansbury 2003), and are converted to stable 
fibrils with an amyloid-like cross-β structure (Conway et al. 2000a, Serpell et al. 2000). 
Fibrillization requires the central portion of αS which forms the protease-resistant core of 
the fibrils (Miake et al. 2002, Der-Sarkissian et al. 2003). The process is nucleation-
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dependent (Wood et al. 1999), seeming to require oxidative dimerization by dityrosine 
cross-linking as a rate-limiting step (Krishnan et al. 2003). 
Fibril formation in vitro is accelerated by diverse factors such as oxidative stress 
(Hashimoto et al. 1999), pesticides (Uversky et al. 2001b), polyvalent metal ions 
(Uversky et al. 2001a), crowding by inert macromolecules (Uversky et al. 2002), tubulins 
(Alim et al. 2002), sGAGs (Cohlberg et al. 2002), phosphorylation at Ser-129 (Fujiwara 
et al. 2002), and truncation of either terminus (Kessler et al. 2003, Murray et al. 2003), 
whereas the formation of soluble oligomers is enhanced by polyunsaturated fatty acids 
(Perrin et al. 2001). Fibrillogenesis is inhibited by β- and γ-synuclein (Uversky et al. 
2002b), as well as by nitration (Yamin et al. 2003) and dopamine (Conway et al. 2001) 
which stabilize oligomeric αS species. Although other lines of evidence also link most of 
the above factors with LB pathology, it is unclear to what degree they might influence αS 
fibrillization in vivo. 
In cell culture, the formation of αS-containing inclusions can be induced and/or 
promoted by a variety of treatments including overexpression (McLean et al. 2000), 
proteasomal inhibition (Rideout and Stefanis 2002), mitochondrial toxins (Lee et al. 
2002), nitrative insult (Paxinou et al. 2001), and transglutaminase cross-linking (Junn et 
al. 2003), but in most studies the sequence of events has not been characterized. 
However, overexpression or rotenone treatment (Lee and Lee 2002, Lee et al. 2002) gave 
rise to small spherical aggregates of nonfibrillar αS throughout the cytoplasm. These 
aggregates, suggested to represent protofibrils, were transported to the juxtanuclear 
region where they coalesced forming a large, fibrillar and stable inclusion enriched in 
mitochondria and lysosomes (Lee and Lee 2002, Lee et al. 2002). This process was 
consistent with an aggresomal response (Johnston et al. 1998), in line with the findings 
that some aggresomal markers colocalize with LBs in PD and DLB brains (McNaught et 
al. 2002b). Nevertheless, a marked disparity remains between the morphologies of 
authentic LBs and aggresomes seen in vitro (Lee et al. 2002), suggesting that LB 
formation involves mechanisms poorly mirrored by the cellular models. 
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2.4 Physiology of p62 
The p62 protein is a cytosolic, conserved protein with an apparent molecular weight of 
~62 kD and bearing no overall homology to other proteins. It was first identified in 
studies of mitogenic signaling as a ligand of the tyrosine kinase p56lck (Park et al. 1995). 
Thereafter, in studies on other aspects of cellular physiology, p62 has been identified in 
several different fields where regulatory proteins have been searched for signaling 
proteins, ion channels, and transcription factors. Most studies to date implicate p62 in the 
regulation of atypical protein kinase C (aPKC), but many poorly understood aspects 
remain about its physiological role. 
For historical reasons, the p62 gene/transcript/protein is referred to with several different 
names. While the approved gene name is “sequestosome 1” (SQSTM1), alternative 
names in use include “aPKC-interacting protein p62”, “ubiquitin-binding protein p62”, 
“zeta-interacting protein” (ZIP), and “A170”. The latter two names also refer to the rat 
and mouse counterparts, respectively. In the remainder of this text, “p62” will be used to 
denote the gene/transcript/protein irrespective of species. It should be noted that in other 
fields, the labels “p62” and “ZIP” are being used in reference to proteins unrelated to 
SQSTM1. 
2.4.1 Structure 
In the human genome, the p62 mRNA is transcribed from a single gene (GeneID no. 
8878. Entrez. The Life Sciences Search Engine 2004) comprising 8 exons that encode a 
protein of 440 amino acids (Joung et al. 1996, Vadlamudi and Shin 1998). The sequence 
contains a number of regions suggestive of functional motifs or domains, including a 
PB1 domain that embeds an OPCA motif, a ZZ zinc finger, two PEST sequences, and a 
UBA domain (Fig. 1a). PB1 domains are present in many cytoplasmic signaling proteins 
and mediate the formation of heterodimeric complexes between PB1 domain-containing 
proteins (Ito et al. 2001, Ponting et al. 2002). The majority of PB1 domains also contain 
an OPCA motif, an acidic region necessary for heterodimerization (Nakamura et al. 
1998, Ito et al. 2001). The ZZ domain encodes a putative zinc finger that is thought to 
mediate protein-protein interactions (Ponting et al. 1996). PEST sequences are 
characteristic of rapidly degraded proteins, many of which serve important regulatory 
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functions (Rechsteiner 1988). The UBA domain is found in diverse enzymes involved in 
the ubiquitination pathway and other systems. It mediates noncovalent binding to mono- 
and poly-Ub but can also bind other proteins and even mediate dimerization (Hofmann 
and Bucher 1996, Bertolaet et al. 2001, Buchberger 2002). The sequence of p62 also has 
many predicted phosphorylation sites for serine/threonine kinases (Fig. 1a) (Ishii et al. 
1996, Joung et al. 1996), but it is unclear whether the regulation of p62 involves 
phosphorylation. At least in some cell types, p62 seems to be phosphorylated, likely by 
casein kinase II (Yanagawa et al. 1997). 
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Figure 1. Primary structure, interaction sites, and isoforms of p62. a) Predicted 
functional domains and motifs (adapted from Okazaki et al. 1999). Phosphorylation sites 
are indicated by spheres (white = PKC; grey = casein kinase II; black = MAP kinase; 
dotted = cAMP/cGMP-dependent protein kinase). The possible N-linked glycosylation 
site is indicated by a hexagon. b) Top: Regions 100 % identical in human, rat, and mouse 
homologues. Below: Areas with high similarity to the Drosophila counterpart ref(2)P. c) 
Partially defined sequence stretches encompassing critical residues for protein bindings. 
d) Alternatively spliced isoforms. (From Joung et al. 1996, Vadlamudi et al. 1996, Gong 
et al. 1999, Sanz et al. 2000, Wooten et al. 2001, Avila et al. 2002, Cariou et al. 2002, 
Chang et al. 2002, Ciani et al. 2003, Croci et al. 2003, Lamark et al. 2003, Noda et al. 
2003, Wilson et al. 2003). 
 
The human amino acid sequence is 91 % identical with the rat and mouse counterparts. 
Notably, the sequence contains several stretches that in the three species are 100 % 
identical, suggestive of critical functional roles (Fig. 1b). These areas encompass the 
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OPCA motif, most of the ZZ domain, the C-terminal PEST sequence, and the UBA 
domain. The ZZ and UBA domains also show relatively high similarity to those of 
ref(2)P, the Drosophila homologue of p62 (Fig. 1b) (Okazaki et al. 1999, Avila et al. 
2002).  
Proteins interacting with p62 The p62 protein is capable of a large number of 
noncovalent interactions, as demonstrated using various affinity assays. Its binding 
partners include cell surface receptors (TrkA−C), receptor-associated proteins (RIP, 
TRAF6, p56lck, Grb14), other signaling proteins (PKC-ζ, PKC-λ/ι, PAR-4, MEK5, 
p38MAPK, p120 ras-GAP, NBR1), a transcription factor (COUP-TFII), ion channel 
proteins (Kvβ2, ρ3), Ub, and p62 itself (Park et al. 1995, Marcus et al. 1996, Vadlamudi 
et al. 1996, Puls et al. 1997, Sanchez et al. 1998, Gong et al. 1999, Sanz et al. 1999, Sanz 
et al. 2000, Sudo et al. 2000, Wooten et al. 2001, Cariou et al. 2002, Chang et al. 2002, 
Croci et al. 2003, Geetha and Wooten 2003, Lamark et al. 2003, Noda et al. 2003). For 
most of the interactions, some information on the respective binding sites in p62 has been 
obtained by using mutated constructs (Fig. 1c). Nonetheless, the structural basis 
underlying these interactions is poorly understood, since no crystal/solution structure has 
been published for the entire p62 or many of its binding partners. However, the structure 
of the p62 UBA domain has been determined (Ciani et al. 2003) and can explain the 
noncovalent p62−Ub binding in terms of hydrophobic interaction between Ub and the 
UBA domain (Mueller and Feigon 2002). Some of the remaining interactions can be 
understood based on structural studies on PB1 domain-containing proteins. PB1 domains 
can heterodimerize in a front-to-back arrangement, promoting the interaction of p62 with 
aPKC, MEK5, and NBR1 (Noda et al. 2003, Wilson et al. 2003). Notably, p62 also 
displayed an exceptional propensity for strong PB1-mediated self-association (Lamark et 
al. 2003, Wilson et al. 2003). 
2.4.2 Expression 
Tissue distribution In human tissues, p62 mRNA is ubiquitously expressed (Joung et al. 
1996), consistent with findings from rodents (Joung et al. 1996, Puls et al. 1997, Gong et 
al. 1999, Okazaki et al. 1999, Croci et al. 2003). The distribution of p62 protein has not 
been studied in human tissues, but in the rat, the protein was detected in all tissues tested 
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(Gong et al. 1999). Within rat brain, p62 was mostly expressed in neurons, especially in 
pyramidal cells of the cerebrum and cerebellar Purkinje cells (Nakaso et al. 1999). Four 
alternatively spliced isoforms of p62 have been identified from rat tissues (Fig. 1a, d). In 
comparison to the full-length (ZIP1) isoform, ZIP2 (Gong et al. 1999) and ZIPβ (Cariou 
et al. 2002) lack regions containing the TRAF6 binding site and a PEST sequence, 
respectively, while ZIP3 has a truncated, variant C-terminus (Croci et al. 2003). The 
protein seems to be mostly expressed as the longest isoform (Ishii et al. 1996, Joung et al. 
1996, Puls et al. 1997, Sanchez et al. 1998, Chang et al. 2002). 
Subcellular localization In several cell types, p62 displays a punctate cytoplasmic pattern 
that colocalizes with late endosomes (Sanz et al. 2000, Aono et al. 2003, Geetha and 
Wooten 2003) as well as with the distribution of aPKC (Sanchez et al. 1998, Samuels et 
al. 2001). Since p62 lacks membrane-spanning domains, it probably resides on the 
cytosolic side of the vesicles. The molecular basis underlying the association of p62 with 
late endosomes is not understood. However, studies on PB1 domain-containing proteins 
have suggested that the punctate distribution of p62 requires its oligomerization, while 
aPKCs appear to be anchored into the punctate structures by p62 (Lamark et al. 2003). 
On the other hand, stimulation of cells by growth factors (NGF, EGF, IL-1) caused the 
internalization of the respective receptors (TrkA, EGFR) and receptor-associated proteins 
(IRAK, TRAF6) within endocytic vesicles, resulting in their partial colocalization with 
the vesicular pattern of p62 (Sanchez et al. 1998, Sanz et al. 2000, Geetha and Wooten 
2003, Lamark et al. 2003). This localization of p62 was therefore speculated to reflect a 
function in the endocytic trafficking of receptors. 
Regulation The expression of p62 mRNA and/or protein is induced by diverse 
physiological and exogenous stimuli, including the mitogenic or differentiation-inducing 
factors IL-3, NGF, TGF-β1, serum, PMA, and Ca2+ ionomycin (Lee et al. 1998, Gong et 
al. 1999, Okazaki et al. 1999), proteasome inhibitors (Ishii et al. 1997), oxidative stress-
generating agents (Ishii et al. 1996, Ishii et al. 2000), and glycol ethers (Syed and Hecht 
1998). The rapid induction of p62 expression by some of these stimuli justify the 
classification of p62 as an immediate early response gene (Lee et al. 1998). The 
regulatory regions of the human p62 gene harbor CpG islands (Vadlamudi and Shin 
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1998), characteristic of highly regulated genes essential for cell vitality (Bird 1986). 
Accordingly, the 5’ regions flanking the transcribed sequences in human and mouse 
genes contain putative binding sites for transcription factors including AP-1, Sp1, NF-
κB, c-myc, Ets-1 family, NF-E2, MyoD, and C/EBP, possibly accounting for the 
responsivity of p62 expression to the above-mentioned stimuli (Vadlamudi and Shin 
1998, Okazaki et al. 1999). However, the regulation of the p62 transcript level also seems 
to involve mRNA stabilization (Lee et al. 1998). 
2.4.3 Functions 
Currently, the best-characterized aspects of p62 function are found in the context of 
aPKC regulation, where p62 has been implicated in the engagement of aPKC in response 
to cell-surface receptor stimulation and in the aPKC-mediated modulation of ion 
channels. However, other activities apparently unrelated to aPKC have also been 
described for p62. Knowledge on its physiological role is mostly based on in vitro 
studies, since mice ablated for the p62 gene were only described recently (Duran et al. 
2004). 
2.4.3.1 Regulation of atypical protein kinase C 
Atypical PKCs (PKC-ζ and PKC-λ/ι) play critical roles in the control of cell growth, 
differentiation, survival, and polarity, as well as glucose transport (Wooten 1999, Moscat 
and Diaz-Meco 2000, Farese 2002, Etienne-Manneville and Hall 2003). These effects are 
partly mediated by aPKC-dependent regulation of gene expression via key signaling 
pathways (Hirai and Chida 2003, Suzuki et al. 2003). In particular, aPKC plays an 
important role in the activation of NF-κB (Diaz-Meco et al. 1993, Leitges et al. 2001), a 
transcription factor involved in a range of cellular functions including inflammatory and 
immune responses and regulation of cell survival (Karin and Lin 2002). This effect of 
aPKC is assumably exerted via the activation of IKKβ (Lallena et al. 1999). The activity 
of aPKCs is regulated by extracellular stimuli (Farese 2002, Hirai and Chida 2003, 
Suzuki et al. 2003), but the mechanisms determining the target specificity of aPKCs are 
largely unclear. However, many protein kinases are regulated by adapter, anchoring, and 
scaffold proteins, which confer specificity to the kinase by determining its site of action 
or by bridging it to target proteins (Pawson and Scott 1997, Mochly-Rosen and Gordon 
 47 
1998, Garrington and Johnson 1999). Several studies suggest that p62 may serve as an 
adapter or scaffold for aPKC. 
NF-κB activation The observations that p62 could bind aPKC (Puls et al. 1997) but 
appeared to be neither its substrate nor a regulator as such (Sanchez et al. 1998) lead to 
several studies which demonstrated a critical role for p62 in signal chains that activate 
NF-κB via aPKC in response to growth factors. First, p62 was implicated in the 
activation of NF-κB by TNFα, known to require aPKC. Upon stimulation by TNFα, p62 
was found to bridge aPKC to RIP, one of the proteins recruited to the TNFR1 receptor 
(Sanz et al. 1999). Thereby, a novel signal chain from TNFα to NF-κB activation was 
established, with p62 as an essential intermediary. Collectively, the findings suggested a 
model in which TNFα stimulation induces the assembly of a receptor-signaling complex, 
involving the interactions TNFR1−TRADD−RIP−p62−aPKC, resulting in the aPKC-
mediated activation of downstream events towards NF-κB activation (Sanz et al. 1999). 
Subsequent studies revealed that p62 plays an analogous role in the activation of NF-κB 
in response to IL-1 and NGF. Thus, upon stimulation by IL-1 (Sanz et al. 2000) or NGF 
(Wooten et al. 2001, Mamidipudi et al. 2002), p62 associated with and linked aPKC to 
the respective receptor-signaling complexes and was necessary for NF-κB activation. In 
the case of IL-1, p62 interacted with the receptor-associated protein TRAF6. The 
findings suggested that IL-1 induces the formation of a receptor-signaling complex in 
which the signal is transduced from TRAF6 via p62 to aPKC (Sanz et al. 2000). Upon 
NGF stimulation, p62 interacted simultaneously with TRAF6 and one of the receptor 
proteins (TrkA), but otherwise appeared to serve a similar function in the aPKC-mediated 
activation of NF-κB (Wooten et al. 2001, Mamidipudi et al. 2002). Recently, p62 was 
further shown to be recruited to the TrkB and TrkC receptors (Geetha and Wooten 2003), 
potentially increasing the number of p62-involving signal chains activated by 
extracellular ligands. 
Collectively, the above studies indicate that p62 connects aPKCs to signal pathways 
initiated by several growth factors, by binding to components of the receptor-signaling 
complexes. The association of p62 and aPKC with these complexes occurs in a ligand-
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induced/enhanced manner, consistent with the colocalization of p62 with internalized 
receptors or their associated proteins upon stimulation by growth factors. A common 
pathway initiated by these events leads to the activation of NF-κB and requires both p62 
and aPKC (Sanz et al. 1999, Sanz et al. 2000, Samuels et al. 2001, Wooten et al. 2001, 
Mamidipudi et al. 2002, Geetha and Wooten 2003). This mechanism appears to be highly 
conserved, since the Drosophila counterparts of p62, aPKC, and NF-κB serve analogous 
roles (Avila et al. 2002). Precisely how p62 promotes aPKC activation remains unclear, 
but several studies suggest that the activation of aPKC requires the simultaneous binding 
of p62 to upstream proteins such as TRAF6 (Sanchez et al. 1998, Wooten et al. 2001, 
Cariou et al. 2002, Chang et al. 2002). In this sense, the role of p62 is that of an adapter 
protein (Sanz et al. 2000). 
Consistent with the above scheme, p62 was found to antagonize the effects of PAR-4, an 
inducible inhibitor of aPKC (Chang et al. 2002). By inhibiting aPKC, PAR-4 can 
suppress NF-κB activation, thereby sensitizing cells to apoptosis (Diaz-Meco et al. 1999, 
El-Guendy and Rangnekar 2003). However, both effects were counteracted by 
coexpressed p62. Since PAR-4 and p62 assembled into a ternary complex with PKC-ζ, 
they seem to constitute an antagonistic pair of inducible regulators for PKC-ζ (Chang et 
al. 2002). 
ERK5 pathway In addition to its role in NF-κB activation, p62 seems to be pivotal for 
other cellular events, including the NGF-induced internalization of TrkA and activation 
of the ERK5 pathway (Geetha and Wooten 2003). The mechanisms underlying these 
phenomena are unclear. However, the requirement of p62 was also demonstrated for 
ERK5 activation upon EGF stimulation (Lamark et al. 2003), suggesting that the ERK5 
pathway might constitute a signal chain activated by several p62-recruiting receptors. 
ERK5 is activated by MEK5 (Kamakura et al. 1999, Kato et al. 2000), promoting 
neuronal survival in the CNS (Watson et al. 2001). There is evidence that MEK5 can be 
activated directly by p62 (Lamark et al. 2003, Noda et al. 2003). 
Channel proteins In addition to linking aPKCs to upstream signaling complexes, p62 
appears to bridge PKC-ζ to some of its phosphorylation targets, including two channel 
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proteins. First, p62 and PKC-ζ were implicated in the regulation of voltage-gated K+ 
channel (KV) activity (Gong et al. 1999). In excitable cells, KV channels are responsible 
for establishing the resting membrane potential and for the modulation of action 
potentials. KV channels consist of pore-forming α subunits, associated with β subunits 
serving modulatory and structural functions (Martens et al. 1999). In rat brain, two 
isoforms of p62 were found to bind to KVβ2 (Gong et al. 1999), the most abundant of the 
β subunits. Further investigations demonstrated the assembly of a ternary complex where 
p62 seems to target the phosphorylation activity of PKC-ζ to KVβ2 (Gong et al. 1999). 
Similarly, p62 and PKC-ζ were implicated in the modulation of GABAC receptor 
function (Croci et al. 2003). GABAC receptors are ligand-gated Cl− channels with an 
unclear functional role (Bormann 2000, Zhang et al. 2001). The ρ3 subunit of GABAC 
receptors was found to bind the ZIP3 isoform of p62. Analogous to the case of KVβ2, the 
study provided evidence for the formation of a ternary complex containing p62, PKC-ζ, 
and the channel protein, ρ3 (Croci et al. 2003). 
The above findings from the context of channel proteins are compatible with the view of 
p62 as a scaffold protein (Croci et al. 2003) that directly bridges a protein kinase (aPKC) 
to its targets. At present it is unclear whether the “scaffold” roles of p62 (i.e., interaction 
with aPKC targets) are linked to its “adapter” functions in receptor-mediated signaling. 
2.4.3.2 Noncovalent Ub-binding and “sequestosomes” 
An interesting feature of p62 is its ability to bind noncovalently to Ub via the UBA 
domain (Vadlamudi et al. 1996). Although the highly conserved sequence of the UBA 
domain points to a critical function (Fig. 1b), its physiological role remains unknown. Of 
potential relevance, treatment of HeLa cells with proteasomal inhibitors resulted in the 
enlargement of p62-containing punctate structures into amorphous, membrane-free 
masses that became enriched in Ub-conjugated proteins. These structures were suggested 
to represent an entity that sequesters Ub-conjugated proteins from the cytoplasm, hence 
the term ”sequestosome”, with the proposal that p62 regulates their formation (Shin 
1998). However, scant evidence was provided in support of these claims. Since 
ubiquitination is also involved in ligand-stimulated internalization of cell-surface 
receptors (Hicke 1999), p62 might serve a role in connecting receptor-mediated signaling 
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events to Ub-dependent regulatory mechanisms (Geetha and Wooten 2002). On the other 
hand, the targets of UBA domains may also be proteins other than Ub (Buchberger 
2002).  
2.4.4 Disease associations 
Hepatocytic inclusions The first direct indication of a role for p62 in disease came in the 
context of liver cancer, where the p62 protein was identified as a major constituent of 
intracytoplasmic hyaline bodies (IHBs) in hepatocellular carcinoma (Stumptner et al. 
1999). IHBs are globular, eosinophilic inclusions composed of granulo-filamentous 
material (MacDonald and Bedard 1990). Apart from p62, no other protein species has 
been reported to be consistently found in IHBs. Very little is known about the 
pathogenesis of IHBs and the cause of p62 accumulation therein. However, in IHBs, p62 
was hyperphosphorylated at epitopes similar to those of tau and neurofilaments in AD 
(Stumptner et al. 1999). By analogy with NFTs, this suggests that aberrant 
phosphorylation might contribute to IHB formation. 
In studies on another hepatocytic inclusion type, the Mallory body (MB), p62 was also 
identified as a major constituent (Zatloukal et al. 2002). MBs are associated with a 
variety of chronic liver disorders. They are irregular, variously sized cytoplasmic 
inclusions with a mostly filamentous ultrastructure. MBs are primarily composed of 
misfolded, abnormally phosphorylated and crosslinked cytokeratins, while also 
incorporating stress-inducible proteins including Ub. Many aspects of their pathogenesis 
are poorly understood (Denk et al. 2000, Denk et al. 2001, Stumptner et al. 2001). 
Interestingly, in a mouse model of drug-induced MB formation, p62 was rapidly induced 
and accumulated in hepatocytes before the appearance of any cytokeratin aggregates. The 
growing MBs seemed to incorporate hyperphosphorylated p62 as an early component 
that was as abundant as cytokeratins (Stumptner et al. 2002, Zatloukal et al. 2002). 
Further experiments indicated that p62 associates with aggregated cytokeratins likely via 
binding to Ub chains in the aggregates. Based on these findings it was speculated that 
p62 might participate in a defensive response against misfolded proteins (Zatloukal et al. 
2002). 
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Paget’s disease of bone (PDB) Mutations in the p62 gene have been implicated in the 
etiology of PDB (OMIM entry no. 602080. Online Mendelian Inheritance in Man 2003), 
a skeletal disorder that affects up to 3 % of individuals above 55 (Cooper et al. 1999). 
The disease is characterized by focal increases of bone turnover due to activated 
osteoclasts, causing bone pain, enlargement, and deformities. The etiology is 
heterogenous, involving several genetic loci with likely contributions from 
environmental factors (Hamdy 1995). A missense mutation in p62 was found to account 
for a high proportion of autosomal dominant PDB cases (Laurin et al. 2002). 
Subsequently, five other PDB-causing mutations in p62 were identified, predicted to 
result in amino acid substitution or C-terminal truncation (Hocking et al. 2002, Johnson-
Pais et al. 2003). The mechanisms by which these mutations lead to the disease are not 
known. However, findings on the genetics and pathophysiology of PDB suggest that the 
mutations may result in aberrant activation of NF-κB (Hocking et al. 2002, Laurin et al. 
2002), supported by recent findings from p62 gene-ablated mice (Duran et al. 2004). 
Although all 6 mutations affect the Ub-binding region of p62, the disease-causing effect 
did not appear to stem from a loss of Ub binding (Ciani et al. 2003), suggesting that the 
C-terminal region of p62 may have some as yet unknown functions which can influence 
NF-κB activation. 
Pathological associations based on disease models Work on animal and cellular models 
has indicated other pathological conditions possibly involving p62. First, oxidative 
stress-generating agents were found to upregulate p62 in vitro at both the mRNA and 
protein levels (Ishii et al. 1996, Ishii et al. 1997). Since oxidative stress may contribute to 
excitotoxic injury (Michaelis 1998), the expression of p62 was also examined in a rat 
model of excitotoxicity. In several brain regions, the levels of p62 mRNA and protein 
were mildly to moderately elevated following the excitotoxic insult (Nakaso et al. 1999). 
This increase of p62 levels appeared to be less marked in neurons most vulnerable to 
excitotoxicity, prompting the speculation that p62 might be playing a protective role. 
Thirdly, in studies addressing the molecular basis of the reproductive toxicity of 2-
methoxyethanol and methoxyacetic acid, these glycol ethers were found to rapidly induce 
p62 mRNA expression in Sertoli cells (Syed and Hecht 1998). 
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At present it is difficult to reconcile the pathological roles of p62 with the currently 
available knowledge of its physiology. However, one obvious common feature in the 
findings from hepatocytic inclusions, neoplasias, and the disease models is the elevation 
of p62 expression levels. In this respect, p62 displays a similarity to stress proteins. 
Collectively, the studies on the normal function and pathological associations of p62 are 
compatible with the view that p62 is a stress-responsive protein which, via the 
modulation of aPKC function, normally regulates downstream effectors including NF-
κB, in a manner that may involve Ub-binding as an important feature. In stressful 
conditions, p62 might thereby potentiate receptor-stimulated adaptive processes 
involving aPKC and NF-κB. However, the diversity of its interacting proteins suggests 
that p62 may also possess additional functions. 
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3. AIMS OF THE STUDY 
A characteristic feature of most neurodegenerative disorders is the occurrence of 
proteinaceous inclusions, abnormal accumulations of cellular constituents, within 
neurons and/or glia in the central nervous system. The inclusions are thought to originate 
in close association with the pathological events that lead to neuronal loss or dysfunction 
in these disorders. In order to elucidate the pathogenetic mechanisms underlying 
inclusion formation, it is necessary to identify the key proteins involved and to 
investigate their structure, function, and regulation. In this study, a gene array approach 
and cellular models were first utilized to identify a candidate protein (p62) possibly 
involved in neurodegenerative phenomena, and subsequent experiments proceeded to 
examine the involvement of p62 in disease-associated protein aggregation in the human 
brain. 
The specific aims were as follows: 
1) To identify genes potentially involved in neuronal apoptosis by looking for gene 
expression changes in a cellular model. Subsequently, to investigate how the expression 
of p62 responds to neuropathology-mimicking conditions, by studying the effects of pro-
apoptotic treatments and proteasomal inhibition on the levels of p62 mRNA and protein 
(Study I). The hypothesis regarding p62 expression was that an upregulation occurs 
during both apoptosis and the accumulation of ubiquitinated proteins. 
2) To study the involvement of p62 in human tauopathies (Alzheimer and Pick diseases) 
and synucleinopathies (Parkinson disease, dementia with Lewy bodies, and multiple 
system atrophy), focusing on their characteristic cytoplasmic inclusions (Study II). The 
hypothesis was that p62 is enriched in these inclusions. 
3) To examine in detail the extent of p62 involvement in the various types of neuronal 
pathology typical of Alzheimer disease (i.e., neurofibrillary tangles, neuritic plaques, and 
neuropil threads) (Study III). The hypothesis was that p62 is predominantly incorporated 
into perikaryal as opposed to intraneuritic protein aggregates. 
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4) To elucidate the morphogenesis of Lewy bodies and their relation to pale bodies and 
other types of α-synuclein-containing accumulations characteristic of Parkinson disease, 
using α-synuclein, p62 and ubiquitin as windows into the aggregation process (Study 
IV). The hypothesis was that different forms of perikaryal α-synuclein-containing 
deposits in the substantia nigra evolve sequentially and show differential incorporation of 
p62. 
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4. MATERIALS AND METHODS 
4.1 Neuronal culture (I) 
Mouse neuroblastoma Neuro-2a cells (CCL 131) were obtained from the American Type 
Culture Collection (Manassas, VA, USA). The cells were cultured in Dulbecco’s 
Modified Eagle Medium (Sigma, St. Louis, MO, USA) containing 1000 mg/l D-glucose 
and supplemented with 10 % fetal calf serum (Life Technologies, Rockville, MD, USA), 
100 U/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine. Rat hippocampal 
neurons were prepared from 17-day old Wistar embryos and cultured in B27-
supplemented Neurobasal medium (Life Technologies) containing 100 U/ml penicillin, 
100 µg/ml streptomycin, and 0.5 mM L-glutamine, as described by Brewer et al. (1993). 
Approx. 24 h after plating, apoptosis was induced in exponentially growing Neuro-2a 
cells either by withdrawal of serum or by treatment with okadaic acid (10−30 nM), 
etoposide (8 µM), or trichostatin A (2 µM). Proteasomal inhibitors MG-132, lactacystin, 
and proteasome inhibitor I (PSI) were used at concentrations of 2−5 µM. Rat 
hippocampal neurons were treated with okadaic acid (10 nM) or lactacystin (5 µM) after 
7 days in vitro. All drugs were purchased from Calbiochem-Novabiochem (San Diego, 
CA, USA). Cells were analyzed for nuclear morphology, caspase-3 activity, and DNA 
integrity as previously described (Solovyan et al. 1999). 
4.2 Gene expression analysis using cDNA arrays (I) 
Atlas mouse cDNA expression arrays (Clontech, Palo Alto, CA, USA), containing 588 
cDNA fragments from genes belonging to various functional classes of proteins, were 
used for the identification of genes upregulated during apoptosis. Briefly, Neuro-2a cells 
were cultured in the absence or presence of serum, to obtain apoptotic and control 
cultures, respectively, and total RNA was extracted from the cells after 24 h using TRIzol 
reagent (Life Technologies). 32P-labelled cDNA probes were prepared from 
deoxyribonuclease-treated samples of apoptotic and control RNA and hybridized to a 
pair of arrays according to the manufacturer’s protocol. The 32P signals were detected 
using a Storm PhosphorImager and spot intensities quantified using the ImageQuaNT 
program (Molecular Dynamics, Sunnyvale, CA, USA). For each detectable spot in the 
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array pair, signal intensity ratios (i.e. apoptotic : control) were calculated and compared 
to the signal ratios of control genes represented in the array. 
4.3 Quantitation of p62 mRNA level (I) 
Total RNA was extracted using TRIzol from cultured Neuro-2a cells and rat 
hippocampal neurons. Equal amounts of RNA (10−15 µg) were denatured and resolved 
in an agarose/formaldehyde gel, transferred in 10× saline sodium citrate (SSC) onto a 
Magnacharge positively charged nylon membrane (Osmonics, Westborough, MA, USA), 
and fixed by ultraviolet crosslinking at 120 mJ/cm2 (Stratalinker 2400; Stratagene, La 
Jolla, CA, USA). As a control to ensure equal loading and transfer efficiency, the blots 
were stained with methylene blue to display ribosomal RNA bands (Sambrook et al. 
1989). A 32P-labeled cDNA probe specific for p62 mRNA was prepared from the 
expressed sequence tag clone #576791 (RZPD, Berlin, Germany) using High Prime 
labelling system (Roche Molecular Biochemicals, Indianapolis, IN, USA). The blots 
were prehybridized for 2 h and hybridized overnight at 65 °C in a solution containing 0.5 
M (with respect to Na+) sodium phosphate, 7 % sodium dodecyl sulfate (SDS), 1 % 
bovine serum albumin, and 1 mM ethylenediaminetetraacetic acid. Thereafter, the 
membranes were washed 2 × 15 min in 2× SSC / 0.1 % SDS and 2 × 15 min in 0.1× SSC 
/ 0.1 % SDS at room temperature. The 32P signals were detected and quantified using the 
Storm PhosphorImager and ImageQuaNT program.  
4.4 Immunoblot analysis of p62 and Ub-conjugated proteins (I) 
Neuro-2a cells were washed twice with ice-cold phosphate buffered saline (PBS) and 
lysed in radioimmunoprecipitation buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.1 % 
SDS, 1 % Triton X-100, 0.5 % sodium deoxycholate) supplemented with 1× Complete 
protease inhibitor cocktail (Roche). The lysates were stored on ice for 30 min and 
centrifuged at 10 000 g for 10 min. The supernatant was used for immunoblotting. Rat 
hippocampal neurons were washed twice with PBS, collected in PBS using a rubber 
policeman, and centrifuged at 15 000 g for 20 s. The cell pellet was lysed in PBS 
containing 1 % Triton X-100 and 1× Complete protease inhibitor cocktail. The lysates 
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were stored on ice for 30 min, centrifuged at 12 000 g for 20 min, and the supernatant 
was used for immunoblotting. 
Equal amounts of proteins (10−20 µg) were analyzed in 10 % polyacrylamide-sodium 
dodecyl sulfate gels according to the standard protocol (Sambrook et al. 1989) and 
transferred onto Hybond ECL nitrocellulose membranes (Amersham Pharmacia Biotech, 
Piscataway, NJ, USA) using a Trans-Blot SD semi-dry blotting apparatus (Bio-Rad, 
Hercules, CA, USA) according to the manufacturer’s protocol. The blots were blocked in 
Tris-buffered saline containing 3 % nonfat dried milk and 0.05 % Tween-20, and 
incubated with primary and secondary antibodies according to standard protocols 
(Sambrook et al. 1989). For labeling of p62, rat polyclonal antiserum against the mouse 
homologue A170 (gift from Dr. T. Ishii, Univ. Tsukuba, Japan) was used at a dilution of 
1:2500. Ubiquitin-conjugated proteins were labeled using a rabbit polyclonal antibody 
(Z0458; DAKO, Carpinteria, CA, USA) diluted 1:500. As secondary antibodies, anti-
mouse or anti-rabbit F(ab’)2 immunoglobulin fragments conjugated to horseradish 
peroxidase (Amersham Pharmacia Biotech) were employed. The protein bands were 
visualized using a chemiluminescent detection system (SuperSignal; Pierce, Rockford, 
IL, USA) onto Hyperfilm ECL (Amersham Pharmacia Biotech). 
4.5 Human subjects (II−IV) 
Postmortem adult human brain specimens were obtained from the Kuopio Brain Bank. 
The brain material used for studies II−IV represented a total of 45 subjects autopsied 
during 1991−2000 at the Department of Pathology in the Kuopio University Hospital. 
The subjects and brain areas examined are summarized in Table 2. The studies were 
carried out following the guidelines and with the approval of the National Board for 
Medico-legal Affairs and the Research Ethics Committee of the Kuopio University 
Hospital and the University of Kuopio. 
For study II, specimens were obtained from 4 clinicopathologically diagnosed subjects 
representing tauopathies (definite AD and PiD), and from 7 cases representing 
synucleinopathies (PD, DLB, and MSA). The brain areas selected for analysis were those 
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that typically show high densities of pathological inclusions in these diseases (Table 2). 
The cases are described in more detail in publication II. 
Table 2.  Summary of human postmortem material. 
Study Group N Description 
 
Age (yr) 
 
Brain 
weight (g) 
Postmortem 
delay (h) 
Brain areas 
examined 
 
II 
 
AD 
 
3 
 
definite Alzheimer 
disease 
83.3 
(78−86) 
1067 
(965−1200) 
80 
(48−96) 
entorhinal cortex 
and hippocampus 
 
 
 
 PiD 1 Pick disease 82 820 10 hippocampus 
 
 
 
 PD 2 Parkinson disease 73 (68−78) 
1303 
(1290−1315) 
72 
(48−96) 
midbrain incl. 
substantia nigra 
 
 
 
 DLB 3 dementia with Lewy bodies 
65 
(52−79) 
1222 
(1020−1350) 
48 
(48−48) cingulate gyrus 
 
 
 
 MSA 2 multiple system atrophy 
51.5 
(49−54) 
1348 
(1295−1400) 
48 
(48−48) 
basal forebrain 
and striatum 
 
 
 
III AD 15 
demented; abundant 
neuritic plaques and 
neurofibrillary 
tangles in neocortex
84.9 
(81−97) 
1008 
(740−1400) 
13.6 
(2−104) 
parietal cortex 
(Brodmann’s 
area 39) 
 
 
 
 
 
 
high-
plaque 
non-
demented 
9 
no dementia;  
abundant neuritic 
plaques but no 
tangles in neocortex
84.8 
(82−92) 
1277 
(1085−1410) 
79 
(5−216) 
 
 
 
 
 
 
 
 
 
IV PaB/LB 7 
abundant PaBs 
and LBs in 
substantia nigra 
69 
(57−80) 
1480 
(1150−1640) 
91.9 
(24−206) 
midbrain incl. 
substantia nigra 
 
 
 
 
 
control 3 no pathology in substantia nigra 
69 
(57−80) 
1355 
(1280−1495) 
72 
(72−72) 
 
 
 
 
 
For study III, subjects from the Brain Bank were initially screened using the following 
criteria: 1) age at death > 80 years and 2) abundant neocortical neuritic plaques in silver 
staining. Into the first group (“AD cases”), 15 subjects were selected that in addition to 
criteria 1−2 showed both abundant neocortical NFTs and clinical signs of dementia 
(Table 2). Of the AD cases, 14 met the clinicopathological criteria of the Consortium to 
Establish a Registry for Alzheimer’s Disease (CERAD; Mirra et al. 1991) for “definite 
AD” and 1 for “probable AD”, while Braak stages were 5−6. To examine the possible 
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involvement of p62 in Ub-positive, tau-negative neocortical neuritic plaque pathology, 9 
age-matched subjects were selected that met the above criteria 1−2 but were devoid of 
neocortical NFTs and showed no clinical signs of dementia. These “(high-plaque) 
nondemented cases” met the CERAD criteria for “possible AD”, and Braak stages varied 
from 1 to 4. All cases, as well as methods for neurofibrillary staging, CERAD 
classification, and scoring of neocortical NPs and NFTs are described in detail in 
publication III. 
For study IV, cases from the Brain Bank were prescreened for the extent of nigral LB 
and PaB pathology in midbrain sections stained with haematoxylin-and-eosin (H&E). 
PaBs were identified as globular, weakly eosinophilic cytoplasmic areas that lacked a 
halo and seemed to displace neuromelanin. Of cases showing abundant LBs and PaBs, 
seven were selected for this study (Table 2). In the SN, these cases displayed abundant 
αS pathology (Parkkinen et al. 2003) but no appreciable signs of pathology in tau 
immunolabeling (see below). In addition, three age-matched control subjects, showing no 
nigral inclusions in H&E stain or tau immunodetection, were examined for the extent of 
αS immunoreactivity in histologically normal SN. The cases are described in more detail 
in publication IV. 
4.6 Histological techniques (II−IV) 
Seven-µm-thick serial sections cut from formalin-fixed, paraffin-embedded brain 
specimens were used for all stainings. The antibodies, dilutions, and epitope unmasking 
treatments for immunohistochemistry are described in Table 3. 
Single immunodetection and common stains. Adjacent sections from brain areas of 
interest were rehydrated, subjected to epitope unmasking treatments (for p62 and αS), 
and stained with antibodies specific for p62, Ub, αS, and HP-tau. For the purpose of 
confirming and/or comparing the specificities of the antibodies, immunostainings were 
performed using using 2−4 different antibodies for p62 (II−IV), Ub (III, IV), and αS 
(IV). For detection, the enzyme-conjugated streptavidin-biotin method (Histostain-Plus / 
Histostain-SAP; Zymed) was used, employing either horseradish peroxidase (II−IV) or 
alkaline phosphatase (II) as the enzyme. The chromogens used were 3,3’-
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diaminobenzidine (Zymed; II, III), Vector Red (Vector Laboratories, Burlingame, CA, 
USA; II), or Romulin 3-amino-9-ethylcarbazole (Biocare Medical, Walnut Creek, CA, 
USA; IV). 
Table 3.  Description of antibodies (FA = formic acid, mAb = monoclonal antibody, 
pAb = polyclonal antibody). 
Name, type 
1Epitope 
(immunogen) 
2Pretreatment Dilution Source
NCL-ASYN, 
mouse mAb 
αS 
(human αS1−140) 
autoclave + 
80 % FA, 5 min 1:1000
Novocastra
(Burlingame, CA, USA)
Synuclein-1, 
mouse mAb αS91−99 80 % FA, 60 min 1:1000
Transduction Laboratories
(Lexington, KY, USA)
LB509,  
mouse mAb αS115−122 80 % FA, 60 min 1:100
Zymed
(San Francisco, CA, USA)
AT8, 
mouse mAb 
tau phosphorylated 
at Ser-202/Thr-205 − 1:500
Innogenetics
(Ghent, Belgium)
p62-N,  
guinea pig pAb 
p62, N-terminal 
(human peptide) autoclave 1:500
Progen 
(Heidelberg, Germany)
p62-C,  
guinea pig pAb 
p62, C-terminal 
(human peptide) autoclave 1:500 Progen
ZIP P-15,  
goat pAb 
p62, C-terminal 
(human peptide) autoclave 1:500
Santa Cruz Biotechnology
(Santa Cruz, CA, USA)
p62 lck ligand, 
mouse mAb 
p62 
(human p62257−437) 
autoclave 1:1000 Transduction Laboratories
Z0458,  
rabbit pAb 
free + poly-Ub 
(bovine Ub) − 1:350
DAKO
(Carpinteria, CA, USA)
NCL-UBIQ,  
rabbit pAb 
Ub 
(human Ub) − 1:1000 Novocastra
mNCL-UBIQ, 
mouse mAb 
Ub 
(human Ub) − 1:20 Novocastra
1For unmapped epitopes, immunogen is given in parentheses. 
2Autoclaving conditions: 120 °C for 10 min in 10 mM sodium citrate (pH 6.0). 
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To preclude possible nonspecific staining by the detection reagents, adjacent control 
sections were processed with omission of the primary antibody. These controls were 
invariably blank. After immunostaining, sections were counterstained with Harris’ 
haematoxylin to reveal nuclei. For comparison, adjacent sections were stained with 
Gallyas or Bielschowsky silver impregnation techniques (II, III) or with H&E (II−IV). 
All sections were mounted in DePeX (BDH Laboratory Supplies, Poole, UK). Variations 
in postmortem delay or age of death had no obvious effect on any of the staining patterns. 
Double immunodetection (III). To visualize p62 in combination with either HP-tau or 
Ub, double immunostaining was performed using the Histostain-DS kit (Zymed), 
employing 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium to label p62 and 
3-amino-9-ethylcarbazole to display HP-tau- or Ub-positive structures. As the primary 
antibodies, p62-N, AT8, and NCL-UBIQ were used, respectively. To preclude cross-
reactions, the manufacturer’s protocol for the second staining was modified by using a 
peroxidase-conjugated secondary antibody against mouse or rabbit IgGs (Pierce) for 
detection of HP-tau or Ub, respectively. Control sections with omission of both primary 
antibodies were processed to ensure that no nonspecific labeling resulted from any of the 
detection reagents. To check that the reagents of the second staining neither recognized 
nor were masked by any of the reagents of the first staining, additional control slides 
were included with the omission of either of the primary antibodies. As the dark blue 
precipitate from the first staining might have concealed any cross-reactivity between 
reagents of the first and second stainings, further slides were processed with omission of 
both the first chromogen and the second primary antibody. Neither nonspecific staining 
nor interference between stainings was observed. Nuclei were counterstained with 
haematoxylin. The sections were embedded in Clearmount (Zymed) and coverslipped 
with DePeX. 
Reversible immunodetection and H&E staining (IV). A reversible chromogenic staining 
technique was utilized to enable the comparative visualization of two overlapping 
antigens (p62 and αS) and tissue morphology as revealed by H&E. Briefly, sections from 
representative subjects were immunostained using the p62-N antibody and temporarily 
mounted in DePeX. Photomicrographs were obtained from structures of interest, 
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whereafter the coverslips were unmounted in xylene and the dye was removed in 70 % 
ethanol. The sections were then treated with formic acid to unmask αS epitopes, and 
immunostained using the NCL-ASYN antibody. To preclude cross-reactions, the latter 
antibody was detected using a peroxidase-conjugated antibody against mouse IgGs 
(Pierce), instead of the biotin-amplified system. After counterstaining and mounting, the 
sections were re-imaged, using cellular landmarks to locate the structures imaged for 
p62. After re-imaging, the sections were again unmounted and destained, followed by 
staining with H&E, mounting and imaging for the third time. The controls employed to 
exclude possible artifacts introduced by this staining protocol are detailed in publication 
IV. 
4.7 Microscopic analysis and quantitation (II−IV) 
The stained sections were analyzed using a Nikon Optiphot-2 microscope. For 
quantitation of the immunopositive structures (III), sections were first scanned at 40× 
magnification to locate the area of gray matter showing the highest involvement. From 
this area, the abundances of NFTs, NPs, and NTs were then scored by counting or visual 
estimation of 3 or 10 adjacent microscopic fields at 200×−40× objective, depending on 
the frequency of labeled structures, as specified in publication III. 
4.8 Photomicrography (II−IV) 
Digital photomicrographs were obtained using a microscope-attached Nikon Coolpix 990 
camera. Image brightness, contrast, and color levels were moderately adjusted using the 
Adobe Photoshop 5.5 program to restore the perceived quality of the microscopic view. 
In study II, identification and comparison of the same cellular structures visualized using 
different stains in adjacent sections were accomplished by alignment of 
photomicrographs taken from the successive sections. In publications II−IV, 
photomicrographs with representative staining patterns are shown for each stain and 
group of subjects. 
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4.9 Statistical analysis (I, III) 
Data was analyzed using SPSS for Windows (release 7.5.1). Changes in p62 mRNA level 
at different timepoints were analyzed using one-way ANOVA followed by Bonferroni’s 
post-hoc multiple group comparison (I). Intra-group comparison of means for NFT and 
NP scores was performed using the Wilcoxon signed-rank (2-tailed) test (III). Statistical 
associations between all variables were measured using the 2-tailed Spearman rank 
correlation test (III). To facilitate viewing of data, some of the continuous variables were 
recoded into 3-step-scales (+...+++), defined by the 20th and 80th percentiles (III). 
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5. RESULTS 
5.1 Neuronal apoptosis and p62 expression (I) 
5.1.1 Identification of p62 as a candidate apoptosis-involved gene 
In order to identify genes potentially involved in neuronal apoptosis, Neuro-2a cells were 
subjected to serum deprivation, and changes in mRNA expression were detected using 
Atlas mouse cDNA arrays at 24 h. One of the mRNAs that was upregulated at least ~50 
% in apoptotic cultures corresponded to oxidative stress-induced protein A170 (I: Fig. 1), 
the mouse counterpart of human p62 (GenBank accession nos. U40930 and NM_003900, 
respectively). 
5.1.2 Expression of p62 is upregulated at the mRNA and protein levels by pro-
apoptotic treatments 
To investigate whether the upregulation of p62 is a consistent feature of neuronal 
apoptosis regardless of the type of apoptotic inducer, the expression of p62 mRNA was 
monitored following a range of treatments known to induce apoptosis in Neuro-2a cells, 
i.e., serum deprivation, okadaic acid, etoposide, and trichostatin A (Salminen et al. 1998, 
Solovyan et al. 1999). All treatments increased the level of p62 mRNA markedly during 
12−48 h, with varying time courses (I: Fig. 2A).  
To examine whether a similar induction of p62 expression occurs during apoptosis in 
primary cultured cells, rat hippocampal neurons were treated with okadaic acid. A 
marked increase was seen in p62 mRNA level at 12−24 h (I: Fig. 2B). 
The response of p62 protein expression to certain apoptotic inducers was analyzed by 
immunoblotting to determine whether the upregulation of p62 mRNA was reflected at 
the protein level. In lysates of Neuro-2a cells, the A170 antiserum recognized a 62-kD 
protein, the level of which was increased by serum deprivation or treatment with okadaic 
acid at 12−36 h (I: Fig. 3A, Β). In rat hippocampal neurons, okadaic acid caused a 
similar increase in the level of the 62-kD protein at 24 h (I: Fig. 3C). 
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5.2 Proteasomal function and p62 expression in neuronal cells (I) 
5.2.1 Inhibition of proteasomal activity upregulates p62 mRNA and protein 
The presence of a Ub-binding area in the C-terminal region of p62 and its ability to bind 
Ub noncovalently (Vadlamudi et al. 1996) suggested that p62 might have a regulatory 
function connected to the Ub-proteasomal system. To study whether the accumulation of 
ubiquitinated proteins could affect the expression of p62, Neuro-2a cells were treated 
with proteasomal inhibitors, and the levels of p62 mRNA and protein were monitored. 
The level of p62 mRNA was upregulated at least 2-fold by all three inhibitors tested (I: 
Fig. 4A). In the case of MG-132, p62 mRNA reached a steady state as early as 6 h, 
whereas lactacystin increased p62 mRNA continuously during 0−24 h. The highest 
upregulation, over 4-fold, was obtained with PSI. In rat hippocampal neurons, lactacystin 
upregulated p62 mRNA by a comparable magnitude at 12−24 h (I: Fig. 4D, upper 
panels). 
At the protein level, p62 expression was similarly increased in Neuro-2a cells by all three 
proteasomal inhibitors, with a maximum at 24−36 h (I: Fig. 4B). Comparable results 
were obtained in rat hippocampal neurons (I: Fig. 4D, lower panel). In the case of PSI, a 
higher Mw band appeared at ~70 kD (I: Fig. 4B, bottom panel), possibly representing p62 
conjugated to monoubiquitin.  
5.2.2 Upregulation of p62 vs. increase of Ub-protein conjugates 
To examine the relationship between p62 upregulation and the amount of Ub-protein 
conjugates, the latter were visualized by immunoblotting. In Neuro-2a cells subjected to 
proteasomal inhibition, a pronounced increase in the level of Ub-immunoreactive 
proteins during 12−36 h was evoked by PSI (I: Fig. 4C), as well as by MG-132 and 
lactacystin. Similarly, in rat hippocampal neurons, proteasomal inhibitors potently 
increased the amount of Ub-immunoreactive proteins, peaking at 12 h (I: Fig. 4E). 
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5.3 Incorporation of p62 into disease-associated inclusions in human brain (II) 
The involvement of p62 in cytoplasmic protein aggregates characteristic of two 
tauopathies (AD and PiD) and three synucleinopathies (PD, DLB, and MSA) was studied 
in comparison to HP-tau, αS, and Ub. 
5.3.1 Tauopathies 
In the AD cases, immunostaining for HP-tau, as expected, revealed numerous NFTs and 
dystrophic neurites in the entorhinal cortex and the CA1 region of the hippocampus (II: 
Fig. 1c). A similar pattern was seen for Ub (II: Fig. 1d). The NFTs were also strongly 
immunoreactive for both p62 antibodies, showing a morphology very similar to HP-tau 
and Ub (II: Fig. 1e, f). In contrast, few neurites were labeled for p62. The number of HP-
tau-positive NFTs was somewhat higher compared to p62 or Ub (II: Table 2). No 
immunoreactivity for p62 was detected in deposits of β-amyloid. 
In the hippocampus of the PiD case, labeling for HP-tau visualized strongly 
immunoreactive, globular PiBs in granule cells of the dentate gyrus and some pyramidal 
cells in the CA1−CA3 regions (II: Fig. 1i). A subset of PiBs also stained for Ub, albeit 
more weakly (II: Fig. 1j). In addition, the Ub antibody displayed diffuse perikaryal 
staining in several neurons and distinct granular immunoreactivity in occasional 
pyramidal cells. The p62 antibodies showed moderate labeling of a subset of PiBs, 
mostly with a fuzzy appearance, and weaker diffuse staining in many neurons (II: Fig. 
1k, l; Table 2). 
5.3.2 Synucleinopathies 
In the cingulate gyrus of the DLB cases, immunodetection of α-synuclein (αS) and Ub 
revealed scattered LBs in deeper cortical layers (II: Fig. 2c, d). The LBs were also 
intensely immunopositive for both p62 antibodies (II: Fig. 2e, f), with a staining pattern 
similar to those of αS and Ub. 
In the substantia nigra of the PD cases, αS immunoreactivity was present as robustly 
positive LBs, diffuse cytoplasmic staining, and αS-positive neurites. While Ub 
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immunostaining displayed both LBs and some neurites, immunoreactivity for p62 was 
only observed in LBs (not shown). 
In the MSA cases, αS immunostaining of basal forebrain and striatum showed in white 
matter abundant cells containing glial cytoplasmic inclusions (GCIs), exhibiting a 
variable degree of αS-positivity, and a typically caplike shape (II: Fig. 2i). Staining for 
Ub showed a similar staining pattern (II: Fig. 2j). Immunodetection of p62-C showed 
more distinct labeling of the GCIs in comparison to αS and Ub, while the p62-N 
antibody displayed fewer inclusions and with lower intensity (II: Fig. 2 k, l; Table 2). 
5.3.3 Comparison of HP-tau, αS, Ub, and p62 incorporation 
Overall, the pattern of p62 immunoreactivity associated with the five types of inclusions 
correlated most closely with that of Ub, while differing somewhat from HP-tau and αS 
(II: Table 2). The notable differences between HP-tau and p62/Ub patterns were the 
higher frequency of HP-tau-reactive NFTs in AD and the presence of diffuse p62/Ub-
positivity within hippocampal neurons in PiD. Compared to αS, the pattern of p62/Ub 
differed in PD by showing no diffuse cytoplasmic staining within nigral neurons. 
In contrast to the similarity between p62 and Ub staining patterns in perikaryal 
accumulations, abnormal neurites were generally immunonegative for p62, although Ub 
immunodetecion revealed dystrophic neurites and neuropil threads in AD and αS-
positive neurites in PD. Unlike Ub, immunoreactivity for p62 was also absent from 
aging-related intracellular accumulations not associated with disease, i.e. neuropil grains 
and corpora amylacea. 
The results obtained with both antibodies for p62 were similar apart from three 
differences noted: 1) In AD, p62-N and -C were slightly selective for NFTs located in 
deeper and upper cortical layers, respectively. 2) Both PiBs and nigral LBs stained 
somewhat more numerously for p62-N. 3) In MSA, p62-N displayed markedly fewer 
GCIs and weaker labeling than p62-C. No immunoreactivity for either antibody was 
detected in tissue areas devoid of disease-associated accumulations. 
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5.4 Accumulation of p62 into AD-type neurofibrillary pathology (III) 
A quantitative study was conducted to analyze the extent of p62 incorporation in 
neurofibrillary changes characteristic of AD and in neocortical neuritic plaque pathology 
not presenting with cognitive impairment. 
5.4.1 AD cases 
In parietal cortical sections of the AD cases, immunoreactivity for p62-N and p62-C was 
predominantly observed in NFTs (III: Fig. 1a). Both antibodies displayed the classical 
morphology of NFTs as perikaryal masses from which thin endings sometimes extended 
into proximal neurites. The NFTs also labeled robustly for HP-tau and Ub (III: Fig. 1b, 
c). Similar results were obtained using other antibodies for Ub and p62. Stainings for HP-
tau and p62 displayed similar numbers of NFTs (III: Fig. 2a), whereas the number of 
Ub-positive (Ub+) NFTs was 61 % and 53 % lower compared to HP-tau and p62, 
respectively (p < 0.001 for both). Despite the fewer Ub-staining NFTs compared to HP-
tau or p62, the abundance of p62+ NFTs correlated better with Ub+ NFTs (rs = 0.713, p < 
0.01) than with HP-tau+ NFTs (rs = 0.579, p < 0.05; III: Fig. 2c). 
In contrast to HP-tau and Ub which revealed dense meshworks of neuropil threads (NTs), 
antibodies for p62 did not exhibit any appreciable labeling of NTs (III: Fig. 1a−c). 
However, in 6 cases, a faint network of very thin NTs positive for p62-N was discernible 
at high magnification in laminae II−III and V, but even this was usually not detected for 
p62-C (III: Table 2). No association was found between the presence of p62+ NTs and 
any of the clinical or neuropathological variables, although there was a significant 
correlation between the abundances of HP-tau+ and Ub+ NTs (rs = 0.674, p < 0.01). 
Similar to NTs, neuritic plaques (NPs) were generally unreactive for p62, while 7 cases 
displayed at least one p62+ NP as a cluster of short p62+ neurites (III: Table 2; Fig. 1a, 
inset). However, the mean number of p62+ NPs was only ~1 % compared to HP-tau+ or 
Ub+ NPs (III: Figs. 1b,c and 2b). The abundance of p62+ NPs did not correlate 
significantly with any of the clinical or neuropathological variables. Deposits of β-
amyloid displayed no immunoreactivity for p62. 
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Double immunostainings verified that p62 was almost invariably present in HP-tau-
staining NFTs, and confirmed the general lack of p62 immunoreactivity in NTs and NPs 
(III: Fig. 3a, b). As a whole, the data from the AD cases revealed a large variability in 
the relative amounts of NFTs, NTs, and NPs immunopositive for a given antigen (III: 
Table 2). 
5.4.2 Nondemented cases 
This group consisted of 9 age-matched cases with abundant neocortical NPs but no 
neocortical silver-stainable NFTs nor signs of cognitive impairment. These cases thus 
met the CERAD criteria for possible AD, while Braak stages varied from 1 to 4 (III: 
Table 1). Although the group had shown no neocortical NFTs with silver stain, 6 of the 
cases displayed in the parietal cortical sections early neurofibrillary pathology, i.e., 
occasional HP-tau+ NFTs or NPs (III: Table 3; Fig. 1e). No NTs immunoreactive for HP-
tau, Ub, or p62 were seen in any of the cases. 
The nondemented cases were mostly negative for p62, while occasional p62+ NFTs or 
NPs were detected in 3 cases, all of which were within the HP-tau+ subgroup (III: Table 
3; Fig. 1d). The numbers of p62+ NFTs were similar to those reactive for HP-tau, but no 
Ub+ NFTs were seen (III: Table 3). The case with the highest numbers of p62+ NFTs and 
NPs also showed exceptionally many HP-tau+ NPs (III: Table 3, case 17). 
Immunolabeling for Ub displayed abundant NPs (III: Fig. 1f, i; Table 3), which were 
4−50-fold more frequent than the occasional HP-tau+ ones. The numbers of Ub+ NPs did 
not correlate with either HP-tau+ or p62+ NPs or NFTs. 
Since p62+ and HP-tau+ NFTs were found in similar numbers in two HP-tau+ cases, 
possibly representing preclinical AD, the findings suggested that p62 is incorporated 
early during NFT formation. To test this possibility, an additional nondemented subject 
with Braak stage I was analyzed, displaying occasional NFTs in the transentorhinal 
cortex. Also in this brain area, p62 and HP-tau immunostainings revealed similar 
numbers of NFTs (not shown). 
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5.5 Formation of αS-containing inclusions associated with PD (IV) 
To elucidate the morphogenesis of Lewy bodies and their relationship to other types of 
αS+ accumulations associated with PD, nigral specimens from cases with abundant αS 
pathology were analyzed using immunohistochemistry for αS, p62 and Ub. 
5.5.1 Perikaryal types of αS accumulation 
All cases with abundant nigral pathology showed moderate to severe loss of pigmented 
neurons, neuronal fragmentation, and αS accumulations (NCL-ASYN antibody) 
throughout the SN. Nonstaining neurons were present in numbers similar to those with 
perikaryal αS accumulations (IV: Fig. 1B−V). Two main types of perikaryal 
accumulation were distinguished, referred to below as punctate αS (IV: Fig. 1B, C) and 
compact inclusions. The latter could be divided into spherically symmetric, intensely 
immunoreactive types (IV: Fig. 1S−V), and less rounded or irregular, somewhat less 
immunoreactive forms (IV: Fig. 1G−L). As the spherical types were mostly consistent 
with classical LBs, they will be referred to as “LBs”. Most of the non-symmetrical 
inclusions conformed to the morphological criteria of PaBs (Pappolla et al. 1989, Gibb et 
al. 1991). Although many did not fully meet these criteria, all non-symmetrical forms 
showed a similar level of immunoreactivity for αS, as well as for p62 and Ub, and will 
be referred to as “PaBs”. 
Punctate αS Punctate perikaryal immunoreactivity consisted of intensely αS+ granules 
(dia. 0.5−1 µm) of varying density (IV: Fig. 1B, C). The granules were generally 
dispersed throughout the perikaryon, sometimes including proximal dendrites, but 
usually lay more sparsely in pigmented areas. Punctate αS was often accompanied by 
faint diffuse labeling, but the latter was not seen without punctate αS. Perikarya 
displaying only punctate αS but no compact inclusions typically accounted for one-third 
of αS+ somata. Punctate αS was also seen in most somata harboring compact inclusions 
(IV: Fig. 1G−V). 
In neurons containing punctate αS but no typical PaBs or LBs, the area with punctate αS 
occasionally encompassed a small, irregular body (IV: Fig. 1D−F). These appeared as 
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“aggregation centers” of the αS+ granules, possibly representing a transition from 
punctate to compact accumulation. These structures were distinct from LBs, whereas the 
larger ones resembled small PaBs (IV: compare Figs. 1F, G). 
Compact inclusions LB-type inclusions usually displayed a concentric laminar 
morphology 4 to ~20 µm in diameter (IV: Fig. 1S−V). Of all compact perikaryal 
inclusions, LBs represented about one-third, while the majority belonged to the diverse 
PaBs. These were generally larger, globular to irregular, with granular to homogeneous 
texture and clearly demarcated to ill-defined outlines (IV: Fig. 1G−L). Recurring patterns 
could be identified, including “uniformly granular” and “arch-like” forms (IV: Fig. 1J, 
K), and a roundish type with strongly staining, unbroken periphery (IV: Fig. 1L). The 
appearances of the latter two types suggested that their peripheral regions were 
undergoing progressive condensation. 
LBs and PaBs often coexisted in the same perikaryon. In addition, a variety of 
morphologies displayed LB- and PaB-type features within a contiguous mass, giving the 
impression of LB formation within or from a PaB (IV: Fig. 1M−R). Frequently, the 
periphery of a PaB contained small LBs or less discrete spherical foci of pronounced αS-
positivity (IV: Fig. M−P). Sometimes the part of the PaB between the foci was only 
weakly αS+ (IV: Fig. 1R), suggestive of focal compaction of the PaB into several LBs, 
with the disappearance of the intervening material (IV: compare Figs. 1O, R, T). 
5.5.2 Extrasomal types of αS accumulation 
Numerous αS-immunoreactive inclusions also lay outside neuronal bodies, displaying 
globular, fusiform, or drop-like shapes, with near-homogenous to granular texture, 
distinct to fuzzy outlines, and uniform to uneven labeling (IV: Fig. 1W). Since they were 
not surrounded by glia and were clearly αS+, these inclusions probably lay within 
neuronal processes (Iseki et al. 2000). Punctate αS, in contrast, was never seen outside 
perikarya and proximal dendrites. Immunoreactivity for αS was further present as mostly 
thin αS+ neurites (IV: Fig. 1X) and in many neuronophagic events (IV: Fig. 1Y). Similar 
results were obtained using the Synuclein-1 antibody. The LB509 antibody was 
exceptional in that it displayed no punctate αS. 
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5.5.3 Selective incorporation of p62 into compact somal inclusions 
In compact perikaryal inclusions, the immunoreactivity for the p62-N antibody was very 
similar to that of αS, revealing variform PaBs, PaB/LB intermediates, and LBs (IV: Fig. 
2B−K). In contrast, neither punctate accumulation nor extrasomal inclusions were 
detected, and only occasional short neurites were labeled. Similar results were obtained 
using three other antibodies for p62, with the exception that one (p62 lck ligand) labeled 
somewhat more neurites. 
Unexpectedly, p62 antibodies displayed the most robust labeling in small inclusions 
within neuronal nuclei (IV: Fig. 2L). Based on their size, shape, and immunoprofile 
(αS−/Ub+), these inclusions could be identified as Marinesco bodies (MarBs) (Bancher et 
al. 1989b, Fujigasaki et al. 2001). Some nuclei with MarBs also exhibited diffuse 
staining (IV: Fig. 2L). 
Sequential staining of p62 and αS verified that compact perikaryal inclusions were 
invariably p62-immunoreactive, with a close similarity between αS and p62 staining 
patterns (IV: Fig. 3E−K). Areas of punctate αS generally did not label for p62 (IV: Fig. 
3B), but focal p62-positivity was seen at “aggregation centers” of punctate αS (IV: Fig. 
3C, D). All extrasomal inclusions and most αS+ neurites were devoid of p62 (IV: Fig. 
3K, F). MarBs were αS-negative (IV: Fig. 3L). 
5.5.4 Accumulation of Ub is less selective compared to p62 
In perikaryal inclusions, the patterns of Ub immunoreactivity resembled those of p62, 
with the exception that the inclusions appeared more fuzzy, and in LBs, the labeling was 
more centrally distributed (IV: Fig. 4B−K). The overall sensitivity of Ub 
immunodetection, however, was lower in comparison to p62. In contrast to p62, 
extrasomal inclusions labeled robustly (IV: Fig. 4L). Neurites were stained in numbers 
intermediate between αS and p62. The immunoprofiles for the different αS+ deposits are 
summarized in Table 3 of publication IV. Ub immunolabeling also revealed MarBs but 
in fewer numbers than seen for p62. 
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5.5.5 Comparison of αS immunodetection and H&E staining 
Compared to αS immunolabeling, much fewer compact inclusions were positively 
identified using the H&E stain, and neither punctate deposition nor abnormal neurites 
were revealed. Direct comparison of αS and H&E phenotypes by means of sequential 
staining confirmed that only a minority of LBs and PaBs were unambiguously identified 
using H&E (IV: Fig. 5A, C), whereas the majority were poorly defined and/or 
overlapped with neuromelanin (IV: Fig. 5B, D). Most PaBs that were clearly delineated 
by neuromelanin in H&E were uniformly granular and globular (IV: Fig. 5C). Poorly 
delineated PaBs usually corresponded to irregular or non-uniform morphologies for αS, 
often different from the H&E phenotype (IV: Fig. 5D, E). Punctate αS without compact 
inclusions often occupied slightly eosinophilic areas with little or no neuromelanin (IV: 
Fig. 5F). 
5.5.6 Control cases 
The three control cases showed no obvious signs of neuronal loss in the SN. Two cases 
were completely αS-negative, whereas one showed punctate αS within two neurons, 
indicative of very early αS pathology. Neither p62 nor Ub immunoreactivity was 
detected within nigral neurons, apart from MarBs.  
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6. DISCUSSION 
In the present series of studies, p62 (sequestosome 1) was identified and selected for 
investigation since this protein possesses several features indicating that it may have a 
possible role in neuropathological conditions. The expression of p62 was first examined 
in neuropathology-mimicking cellular models (study I). The involvement of p62 was 
then characterized in disease-associated protein aggregation in the human brain, focusing 
on cytoplasmic inclusions occurring in tauopathies and synucleinopathies (studies 
II−IV).  
6.1 Methodological considerations 
Cellular models The cell types used in study I have been widely employed for in vitro 
modeling of diverse neuropathological phenomena, including apoptosis (Krohn et al. 
1998, Kim et al. 2000) and proteasomal impairment (Fenteany and Schreiber 1996, 
Keller and Markesbery 2000). To preclude possible cell type-specific effects or artefacts 
arising from the use of immortalized (Neuro-2a) cells, the main findings were confirmed 
in primary cultured (rat hippocampal) neurons. However, it is obvious that both the 
neuropathology-mimicking treatments as well as the cellular responses in these models 
are likely to differ in several ways from their counterpart events in vivo, for instance by 
being more acute and pronounced. Nonetheless, the models serve as useful indicators for 
novel phenomena with potential relevance for human disease. 
Neuropathological studies Data obtained from postmortem tissues may be influenced by 
artefacts due to agonal and postmortem events and variations in tissue processing. The 
epitopes and pathological structures probed by the antibodies in studies II−IV seemed to 
be relatively insensitive to the length of the postmortem delay (PMD). In study III, none 
of the immunodetection-based variables correlated with PMD, and in study IV, variations 
in PMD had no obvious qualitative effect on the labeling patterns. Any effects arising 
from agonal events or tissue processing also seemed to be negligible in the cases 
examined, since no anomalies were seen in the staining results for any of the antibodies.  
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The specificity of immunodetection was ensured by employing well-characterized and/or 
widely used antibodies (e.g., AT8 and LB509) and by using multiple antibodies per 
antigen, in particular for p62 in each study and for αS in study IV. The use of multiple 
antibodies per antigen also served to eliminate the possibility of false negative results that 
might be caused by masked or modified epitopes. In double (III) and sequential (IV) 
immunolabeling, a number of controls were utilized to exclude possible cross-reactivity 
between the staining reagents for different epitopes. 
Immunohistochemistry is inherently limited by being only semi-quantitative, with a low 
dynamic range. In studies II−IV, the sensitivity of immunodetection was therefore 
adjusted for optimal visualization of pathological changes of interest (i.e., inclusions), 
whereas the normal expression of the proteins remained below the detection level, as is 
evident from the virtual absence of background staining. Consequently, the pathological 
accumulation visualized is considered to represent greatly elevated focal densities of the 
proteins, as compared to their physiological distribution. On the other hand, it is possible 
that less conspicuous types of protein buildup may have gone unnoticed. 
In study IV, an attempt was made to reconstruct the morphological sequence of events in 
LB formation by performing a tentative ordering of immunostained structures. An 
essentially similar approach has been employed in the case of NFTs (e.g., Bancher et al. 
1989a). Although a range of apparently intermediary forms were observed that suggested 
a particular sequence, the ordering nevertheless remains subjective and relies on several 
assumptions about the nature of the process (e.g., unidirectional and stereotypical). More 
direct tracing of the events will require the development of novel experimental models, 
since those currently available do not duplicate the morphology of PD-associated 
inclusions to a satisfactory degree. 
Obviously, neuropathological studies do not allow the elucidation of the underlying 
molecular mechanisms. However, while descriptive in character, the data provided will 
be instrumental for the testing of current hypotheses and for the delineation of novel 
concepts. 
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6.2 Expression of p62 in neuropathology-mimicking models (I) 
6.2.1 Neuronal apoptosis and p62 expression 
The initial cDNA array observation of an increase in p62 mRNA upon serum deprivation 
of Neuro-2a cells was confirmed and extended by the findings that several different 
apoptosis-inducing treatments (i.e., serum deprivation, okadaic acid, etoposide, and 
trichostatin A) cause a prominent upregulation of p62 at both the transcript and the 
protein levels. Since consistent findings were obtained in rat hippocampal neurons, the 
findings suggested that the induction of p62 expression might be a common event in 
neuronal apoptosis also in vivo. These were the first reported data linking neuronal 
apoptosis to changes in p62 expression. 
As such, the present findings, associating the upregulation of p62 with apoptosis, neither 
reveal the mechanisms accounting for this increase nor indicate directly whether the 
upregulation of p62 is functionally involved in, or is unrelated to the apoptotic response. 
While each of the 4 treatments used induces apoptosis (Salminen et al. 1998, Solovyan et 
al. 1999), it could be argued that they might upregulate p62 expression via separate 
pathways not necessarily linked with apoptotic signaling. However, in that scenario, a 
consistent upregulation of p62 by the different pro-apoptotic conditions, each of which 
elicits distinct primary events, would be unlikely, and thus this favors the involvement of 
common events behind the upregulation of p62. Furthermore, these putative common 
events need not be specific to apoptosis. Indeed, while no other work addressing p62 
expression in apoptosis has been reported to date, an elevation of p62 level was observed 
in several models of pathological conditions, including exposure in vitro to oxidative 
stress-generating agents (Ishii et al. 1996, Ishii et al. 1997) or glycol ethers (Syed and 
Hecht 1998) and in vivo to excitotoxic insult (Nakaso et al. 1999) or the MB-inducing 
drug 3,5-diethoxycarbonyl-1,4-dihydrocollidine (Stumptner et al. 2002). Since it is 
upregulated upon oxidative stress, p62 was referred to as a “stress protein” by Ishii et al. 
(1997), although it is clearly structurally distinct from the established types of stress 
proteins such as the heat shock proteins. Nevertheless, the responsiveness of p62 to 
diverse stimuli that impose stress upon the cell is consistent with the possibility that the 
upregulation of p62 may manifest a stress-related response. 
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It is tempting to speculate that a common mediator for the upregulation of p62 might be 
oxidative stress, since reactive oxygen species (ROS) are generated in each of the 
pathological p62-inducing conditions (Michaelis 1998, Syed and Hecht 1998, Denk et al. 
2000), including apoptosis (Sastry and Rao 2000). In line with this, the induction of p62 
expression in the present study clearly preceded the activation of caspase-3 in these 
models (Salminen et al. 1998, Solovyan et al. 1999) and thus paralleled more upstream 
events that involve ROS generation (Greenlund et al. 1995, Schulz et al. 1997). 
Oxidative stress may induce p62 expression via redox-sensitive transcription factors that 
have binding sites in the p62 promoter region (Vadlamudi and Shin 1998, Okazaki et al. 
1999) and/or via the stabilization of p62 mRNA (Lee et al. 1998). One of the critical 
factors appears to be Nrf2, since ROS-generating agents increase its activity and since 
the ablation of the Nrf2 gene largely cancels ROS-induced upregulation of p62 (Ishii et 
al. 2000). Nrf2 is a subunit of the NF-E2 transcription factor that has binding sites in the 
regulatory regions of the p62 gene. Interestingly, Nrf2 is essential for the coordinated 
transcriptional activation of detoxication enzymes that contribute to defense mechanisms 
against oxidative stress (Itoh et al. 1997a, Nguyen et al. 2003b). The increase of p62 
expression may also receive contributions from other redox-sensitive factors such as NF-
κB (Ishii et al. 2000), likewise activated by ROS (Kaltschmidt et al. 1999), although their 
roles in the regulation of p62 have not been addressed. It is noteworthy that NF-κB not 
only seems to regulate transcription from the p62 gene, but is also itself activated in a 
p62 protein-dependent manner (Sanz et al. 1999), suggesting the presence of a feedback 
mechanism that controls the parallel activation of p62 and NF-κB. However, in addition 
to the ROS-mediated pathways outlined above, the pro-apoptotic treaments used in the 
present study may also influence the expression of p62 via stimulus-specific pathways, 
possibly explaining the varying time courses of p62 upregulation. 
The implication of p62 in aPKC-mediated activation of NF-κB, currently the best-
characterized aspect of p62 function, provides one attractive framework for interpreting 
the significance of the present findings. It would be expected that conditions which 
elevate the level of p62 should also result in the enhancement of NF-κB activation and 
other signaling downstream from p62, such as ERK5 activation. Indeed, upon oxidative 
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stress, both NF-κB (Li and Karin 1999) and ERK5 (Abe et al. 1996) are activated. Since 
both NF-κB (Wooten 1999, Foehr et al. 2000) and ERK5 (Watson et al. 2001, Liu et al. 
2003) act as survival factors in neurons, another predicted consequence would be the 
enhancement of neuronal survival. Accordingly, three in vitro studies suggest that the 
upregulation of p62 has survival-promoting effects. In HEK and PC12 cells, 
overexpression of p62 potently enhanced NF-κB activation and antagonized cell death, 
while the opposite was seen with antisense p62 (Wooten et al. 2001). Overexpressed p62 
also antagonized PAR-4-mediated inactivation of NF-κB and apoptosis (Chang et al. 
2002). In addition, overexpression of p62 in PC12 cells enhanced the activation of ERK5 
(Geetha and Wooten 2003). In vivo, indirect evidence for a protective role for p62 against 
cell death was obtained in a rat model of excitotoxicity, where an inverse correlation was 
seen between the degree of p62 upregulation and the vulnerability to the excitotoxic 
insult (Nakaso et al. 1999). 
Taken together, the above considerations suggest a scheme in which various conditions 
that involve the generation of ROS may, possibly via the activation of redox-sensitive 
factors such as Nrf2, induce the expression of p62, which in turn potentiates pro-survival 
signaling via pathways including the activation of NF-κB and ERK5. Viewed in this 
context, the present findings suggest that the upregulation of p62 is a common event in 
neuronal death-promoting conditions and is involved in the activation of protective 
signaling.  
6.2.2 Proteasomal function and p62 expression 
As the reported ability of p62 to bind noncovalently to Ub (Vadlamudi et al. 1996) 
pointed to a functional role in ubiquitination-mediated processes, it was of interest to see 
how the expression of p62 responds to conditions in which Ub-conjugated proteins 
accumulate. The proteasomal inhibitors MG-132, lactacystin, and PSI prominently 
increased the expression of p62 at both mRNA and protein levels in Neuro-2a cells. 
Similar results were obtained in hippocampal neurons, suggesting that the upregulation 
of p62 is a common event in neurons subjected to proteasomal inhibition. These were the 
first data showing a response in p62 mRNA expression to proteasomal inhibitors. 
Previously, Ishii et al. (1997), using 5−20-fold higher concentrations of inhibitors, had 
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reported an induction of p62 protein, to a degree comparable to that in our study. 
However, since any protein normally degraded via the proteasome is likely to accumulate 
upon proteasomal inhibition, analysis of protein levels alone is not very informative. In 
contrast, the observed increase at the transcript level of p62 might signify a functional 
response specifically involving p62. Our findings on both mRNA and protein levels are 
consistent with those more recently obtained in normal and transformed breast epithelial 
cell lines (Thompson et al. 2003). 
As expected, the proteasomal inhibitors also caused a marked accumulation of Ub-
conjugated proteins in both types of neuronal cells. These findings raised the possibility 
that the upregulation of p62 could represent a response to the concomitant increase in the 
level of ubiquitinated proteins, as would be expected if the function of p62 involves 
interactions with Ub. The latter assumption is currently not substantiated in the light of 
the work that has established a physiological role for p62 in aPKC-mediated signal 
transduction, yielding functional models that assign no significance for the Ub-binding 
ability of p62 (Sanz et al. 1999, Sanz et al. 2000, Wooten et al. 2001, Mamidipudi et al. 
2002). However, it should be noted that the findings from the context of PDB (Ciani et 
al. 2003) as well as the highly conserved sequence of the UBA domain of p62 (Avila et 
al. 2002) point to the importance of the UBA region for the normal functioning of p62. 
Accordingly, it has been suggested that an interaction of p62 with ubiquitinated receptor-
associated proteins might play an important role in receptor-mediated signaling (Geetha 
and Wooten 2002, Mamidipudi and Wooten 2002), but such putative interactions remain 
to be characterized. 
It is likewise unclear what mechanisms underlie the observed elevation of p62 level upon 
proteasomal inhibition. It is not known if a sensor mechanism exists that would monitor 
the level of Ub-conjugated proteins and, upon their accumulation, would induce adaptive 
changes in gene expression. However, when the expression of p62 protein was compared 
to the level of ubiquitinated proteins in normal and cancerous breast specimens, no 
correlation was found (Thompson et al. 2003), suggesting that the amount of Ub 
conjugates is not a major determinant for p62 expression, although the result may have 
been confounded by the inclusion of neoplastic tissues in the analysis. In any case, 
proteasomal inhibition results in other events that may account for the upregulation of 
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p62. For example, it causes the buildup of transcription factors that are normally 
degraded via the proteasome (Hochstrasser and Kornitzer 1998). Interestingly, as noted 
by Aono et al. (2003), proteasomal inhibitors mimick other stress agents by inducing the 
accumulation of Nrf2, with the consequent induction of Nrf2-driven genes (Nguyen et al. 
2003a, Stewart et al. 2003). A similar mechanism may apply for other transcription 
factors such as AP-1 (Wu et al. 2002) and C/EBP (Hungness et al. 2002) that are 
activated upon proteasomal inhibition and target the p62 promoter. In addition, 
proteasomal inhibition leads to the production of reactive oxygen and nitrogen species 
(Lee et al. 2001a, Hungness et al. 2002) and might thereby activate pathways similar to 
those initiated by oxidative stress. On the other hand, in a promoter activity assay, 
proteasomal inhibitors did not affect the basal transcription activity of p62 despite 
increasing its mRNA level, suggesting that the increase occurs via mRNA stabilization 
(Thompson et al. 2003). However, the latter results may not be conclusive, since a 
tumorigenic cell line was used and the analysis was confined to a 1.8-kb region in the 
promoter, possibly lacking the elements mediating the response of p62 to proteasomal 
inhibitors. 
Whether or not the upregulation of p62 reflects functional links with Ub, it might also 
possess an adaptive role in the aPKC context, as suggested to be the case in the condition 
of pro-apoptotic stimuli. However, any adaptive role that p62 might serve upon 
proteasomal inhibition should differ from that in the case of pro-apoptotic stresses, since 
NF-κB activation is generally blocked by proteasomal inhibitors (Traenckner et al. 1994, 
Maggirwar et al. 1995). It could also be argued that the processes of apoptosis and 
production of ROS differ fundamentally from the condition of proteasomal impairment in 
the sense that the former are part of normal tissue development and cell metabolism and 
therefore associated with devoted and adaptive cellular responses, whereas the same may 
not be true for overt proteasomal dysfunction, a pathological state lacking counterparts in 
normal physiology. Therefore, the observed upregulation of p62 in this experimentally 
induced condition might also represent a fortuitous event. However, while further studies 
should resolve the functional significance of p62 upregulation upon proteasomal 
inhibition, the findings predict that p62 may similarly accumulate in vivo upon conditions 
involving decreased proteasomal activity. 
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Collectively, the results from study I demonstrated that p62 expression in neurons shows 
a marked responsiveness to two types of pathological conditions relevant to ND 
disorders, i.e., apoptosis-promoting stresses and proteasomal impairment. Together with 
previous work implicating p62 in protein aggregation in liver pathology (Stumptner et al. 
1999), these findings raised the question as to whether p62 might be similarly involved in 
neurodegenerative events in the human brain. 
6.3 Incorporation of p62 into tau- and αS-containing inclusions (II) 
This study was carried out to examine the immunoreactivity of p62 in relation to that of 
Ub, HP-tau, and αS in affected brain areas of human tauopathies (AD, PiD) and 
synucleinopathies (PD, DLB, MSA). The unexpected result of the study was the selective 
accumulation of p62 into each of the cytoplasmic inclusion types characteristic of these 
diseases, i.e., NFTs, PiBs, brainstem and cortical LBs, and GCIs, respectively. Since the 
immunoreactivity for p62 was confined to inclusion-harboring cells in the staining 
conditions employed, the accumulations detected likely represent greatly elevated focal 
amounts of p62 compared to its physiological levels. These findings suggested that the 
pathological aggregation of HP-tau and α-synuclein might share common mechanisms 
involving p62. 
In comparison to previously reported constituents of the above inclusion types, p62 was 
exceptional by showing copious incorporation into both tau- and αS-containing 
perikaryal inclusions yet was generally absent from deposits within neurites (i.e., 
neuropil threads and dystrophic neurites in AD and αS+ neurites in PD). Furthermore, 
p62 immunoreactivity was absent from amyloid plaques as well as from aging-related 
Ub-positive structures not associated with disease (i.e., neuropil grains and corpora 
amylacea). These findings rule out the possibility that p62 would be nonspecifically 
incorporated into all types of protein aggregates or Ub-containing structures and suggest 
that p62 accumulates selectively into disease-associated perikaryal inclusions. 
Little is known about the mechanisms underlying the enrichment of p62 into cytoplasmic 
inclusions. However, when the staining pattern of p62 was compared with those seen for 
Ub and HP-tau or αS in inclusion-containing perikarya (II: Table 2), it appeared that for 
 82 
each inclusion type, the staining pattern of p62 was similar to that of Ub but it exhibited 
some differences in comparison to HP-tau and αS. For example, in the dentate gyrus of 
the PiD case, the robust and globular HP-tau-immunoreactivity of PiBs contrasted with 
the weaker and more diffuse labeling for Ub and p62, whereas in the SN of the PD cases, 
diffuse cytoplasmic immunoreactivity was detected for αS but not for Ub or p62. Apart 
from the fact that abnormal Ub-positive neurites were generally immunonegative for p62, 
the similarity between the staining patterns for p62 and Ub in disease-associated deposits, 
together with the Ub-binding ability of p62 (Vadlamudi et al. 1996), suggested that the 
accumulation of p62 and Ub might be interconnected. 
Based on the findings that p62 proteins can self-associate in vitro with strong affinity 
(Puls et al. 1997), likely causing its oligomerization in vivo (Gong et al. 1999) and the 
formation of large aggregates upon ectopic expression in several cell types (Puls et al. 
1997), we proposed a mechanism whereby dimeric p62 might coaggregate with Ub-
conjugated proteins. As the regions of p62 necessary for self-association and Ub-binding 
lie near the opposite termini of its sequence, we surmised that a p62 dimer would be 
capable of binding two Ub chains simultaneously. Thereby, p62 dimers and Ub-
conjugated proteins might be linked into a net-like arrangement, possibly favoring their 
coaggregation (II: Fig. 3). In this manner, p62 might be sequestered into pathological 
inclusions via binding to ubiquitinated tau/αS or other Ub-conjugated species therein. 
Alternatively or in parallel, Ub conjugates might be redistributed and enriched into 
structures containing p62, as observed in cells exposed to proteasomal inhibitors (Shin 
1998). 
Our assumption that the incorporation of p62 into inclusions reflects binding to Ub was 
corroborated by a study employing a cellular model of intranuclear polyglutamine 
aggregates. These aggregates were shown to recruit normal cellular Ub-binding proteins 
(p62 and ataxin-3), in a manner that required the presence of functional Ub-binding 
motifs (Donaldson et al. 2003). However, it is not known whether the same mechanism 
might apply to inclusions that form in the cytoplasm. Further, although an intact UBA 
domain was shown to be necessary for the recruitment of p62 (Donaldson et al. 2003), it 
should be noted that UBA domains may also bind proteins other than Ub (Buchberger 
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2002, Mueller et al. 2004). Findings from a cell culture model of MB formation were 
also interepreted to suggest Ub-dependent sequestration of p62 (Zatloukal et al. 2002), 
although also these results left open other possibilities, e.g. the direct interaction between 
p62 and misfolded cytokeratins. 
The model based on p62 self-association was also strengthened, albeit with slight 
modification, by structural studies on PB1 domain-containing proteins, showing that PB1 
domains can heterodimerize in a front-to-back arrangement via electrostatic interaction 
(Noda et al. 2003, Wilson et al. 2003). Interestingly, among 8 different proteins studied, 
p62 was exceptional by displaying strong PB1-mediated self-association (Lamark et al. 
2003), resulting in high-molecular weight aggregates in vitro (Wilson et al. 2003). Thus, 
unlike the back-to-back dimers assumed in our model (II: Fig. 3), the front-to-back 
arrangement demonstrated by these studies also seems to enable the chain-like 
oligomerization of p62, while possibly allowing simultaneous interactions with Ub 
(Lamark et al. 2003, Wilson et al. 2003). 
It is conceivable that proteasomal dysfunction, as occurs in AD (Keller et al. 2000) and 
PD (McNaught and Jenner 2001) as well as in vitro upon protein aggregation (Bence et 
al. 2001), might be an underlying factor that contributes to concomitant accumulation 
and aggregation of p62 and Ub. In affected cells, a decline in proteasomal activity might 
be triggered and/or exacerbated by PHF-tau (Keck et al. 2003) or αS (Snyder et al. 
2003), resulting in the accumulation of both p62 and Ub-conjugated proteins, as observed 
in cultured neurons treated with proteasomal inhibitors (study I). The co-accumulation of 
p62 with ubiquitinated proteins would be expected to favor the PB1-mediated self-
association of p62 as well as its interactions with Ub-conjugated proteins including tau 
and αS. In addition to proteasomal dysfunction, the accumulation of p62 might be 
promoted by oxidative stress, which has been implicated in the pathogenesis of both 
neurodegenerative diseases and liver inclusions (Zatloukal et al. 2002). 
Studies on other diseases have revealed further types of p62-immunoreactive inclusions 
(Table 4). In hepatocellular carcinoma, p62 was identified as a major constituent of IHBs 
(Stumptner et al. 1999). After our study, Zatloukal et al. (2002) confirmed the presence 
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of p62 in NFTs and LBs and demonstrated its abundance also in MBs in liver diseases 
and its presence in GFAP-containing Rosenthal fibers in astrocytoma. More recently, p62 
was shown to accumulate into Ub-positive, tau-negative (Ub+/tau−) intraneuronal 
inclusions seen in frontotemporal dementia (FTD) (Arai et al. 2003). In this disease, also 
Ub+ neurites labeled for p62. Similarly, in amyotrophic lateral sclerosis with dementia 
(ALS-D), at least a subset of the Ub+tau− neuronal inclusions in the dentate gyrus and 
neocortical regions were immunoreactive for p62 (Arai et al. 2003, Nakano et al. 2004). 
Notably, in a case with ALS-D, Arai et al. also found p62+ oligodendrocytic and 
astroglial inclusions negative for both Ub and tau. Further, p62 was present in tau+ glial 
inclusions characteristic of PSP and CBD (Arai et al. 2003). 
Based on the above findings, the engagement of p62 appears to be a general feature of 
proteinaceous cytoplasmic inclusions that form within the cytosol. In published work, no 
contrary example has been reported to date. As a rule, p62 also seems to be incorporated 
into most inclusions of each type (Table 4). The only contrasting result was the detection 
by Nakano et al. (2004) of p62 in less than 50 % of the Ub+ neuronal inclusions in ALS-
D. However, the authors used a p62 antibody not recommended for paraffin-embedded 
sections. When the same inclusion type was examined in FTD using two other antibodies 
for p62 and a different epitope unmasking method, similar numbers of p62+ and Ub+ 
inclusions were observed (Arai et al. 2003). It is also noteworthy that p62 serves 
currently as a candidate primary constituent for the Ub+ neuronal and Ub− glial inclusions 
in ALS-D, in addition to the hepatocytic IHBs. 
On the other hand, at least immunohistochemically, the incorporation of p62 seems to be 
more copious and frequent than that of Ub in several inclusion types (Table 4). These 
types comprise the Ub− oligodendrocytic and astroglial inclusions in ALS-D, only 
revealed by p62 immunostaining (Arai et al. 2003), as well as the IHBs which are mostly 
Ub− (Stumptner et al. 1999). Likewise, tau+ glial inclusions labeled positively for p62 
while displaying variable to no immunoreactivity for Ub (Ikeda et al. 1998, Komori 
1999). PaBs and MarBs also showed preferential labeling for p62 in comparison to Ub 
(study IV). Further, the incorporation of p62 seemed to precede that of Ub in NFTs 
(study III) and in MBs (Zatloukal et al. 2002). These observations suggest that p62 may 
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accumulate into inclusions in an Ub-independent manner, the findings being apparently 
contradictory with the coaggregation model presented above. 
The possibility remains that the “Ub-negative” inclusions might contain Ub-conjugated 
proteins in amounts too low to be revealed by conventional immunodetection yet 
sufficient for the recruitment of p62. If this is not the case, it is noteworthy that p62 
seems to be incorporated into inclusions in a manner that requires neither Ub nor any 
particular one of their main constituent species (Table 4). The question therefore arises as 
to the molecular determinant(s) that would account for the incorporation of p62 into the 
manifold inclusions with tau, αS, cytokeratins, GFAP, p62 itself, or unknown proteins as 
their assumed primary constituents. Conceivably, such molecular determinants that are 
common to the misfolded, aggregated proteins in these diseases might be constituted by 
aberrant structural features (e.g., hydrophobic surfaces, oxidized residues, or β-sheet 
conformation), to which p62 might bind either directly or indirectly. The possibility of 
direct binding is intriguing in light of the identification of antibodies that recognize 
common epitopes present in amyloid fibrils or soluble oligomers derived from 
structurally unrelated proteins (O'Nuallain and Wetzel 2002, Kayed et al. 2003). 
Alternatively, p62 might associate with aggregates indirectly, via binding to a chaperone 
protein, for example, since various types of chaperones are recruited to misfolded 
proteins (Richter-Landsberg and Goldbaum 2003). 
Thus, findings to date provide evidence for both Ub-dependent and -independent 
mechanisms to explain the deposition of p62 into cytoplasmic inclusions. It is possible 
that both mechanisms might be involved. Be that as it may, it is important to point out 
that if p62 binds as oligomers to its target proteins in the aggregate, this would be 
expected to result in strong, multivalent interaction of p62 arrays with the target proteins, 
by analogy with high-avidity bindings between multivalent antigens and antibodies 
(Alberts et al. 1994). Such incorporation of oligomeric p62 might therefore promote the 
compaction of misfolded and/or ubiquitinated proteins into dense inclusions. However, 
the common engagement of p62 into diverse inclusions might also reflect some other, as 
yet unidentified functional role(s), possibly as part of more complex molecular interplay 
(pp. 95−98). 
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Collectively, study II demonstrated the presence of p62 in the hallmark tau and αS 
inclusions of AD, PiD, DLB, PD, and MSA, showing selective accumulation of p62 into 
perikaryal deposits. The observations also suggested that p62 might coaggregate with 
ubiquitinated proteins. These findings spurred more detailed investigations into the 
relation between p62 and other inclusion constituents in the intraneuronal protein 
aggregates characteristic of AD and PD. 
6.4 Involvement of p62 in AD-type neurofibrillary pathology (III) 
In this study the extent of p62 involvement in intraneuronal AD-type pathology was 
examined in the neocortex of demented and cognitively unimpaired aged individuals. 
The first main finding was that within the spectrum of AD-type neuronal lesions, the 
immunoreactivity for p62 appears to be tightly linked to neurofibrillary pathology but 
occurs independently of NP-associated, Ub-positive and AT8-negative (Ub+/AT8−) 
neuritic dystrophy. Thus, in the AD cases, p62 was almost invariably present in NFTs, 
while the nondemented cases were virtually or completely devoid of p62 staining, though 
rich in Ub+/AT8− NPs. The second observation of major interest was that in the AD 
cases, p62 immunoreactivity was almost exclusively confined to perikaryal HP-tau 
aggregates, i.e. NFTs, as opposed to NTs or dystrophic neurites of NPs. This was in clear 
contrast to the staining profiles of HP-tau (AT8) and Ub. These findings strengthened the 
view from study II that p62 accumulates selectively into disease-associated perikaryal 
inclusions, rather than simply associating with any type of focal buildup of Ub. 
It is presently unclear why p62 localizes preferentially in NFTs, as opposed to 
intraneuritic deposits of HP-tau. A similar predilection of p62 for perikaryal vs. 
intraneuritic aggregates was observed in αS pathology (IV). One possibility is that this 
pattern might reflect the normal intraneuronal distribution of p62. However, at least in 
neuronal culture (i.e., NGF-differentiated PC12 cells), endogenous p62 was found in both 
perikarya and neurites (Geetha and Wooten 2003), and it is likely that the same is true for 
neurites in the brain. Further, in FTD, p62 was shown to accumulate into Ub+/tau− 
neuritic sturctures (Arai et al. 2003), previously localized to distal dendrites (Iseki et al. 
1998). These findings may suggest that either the normal intraneuronal distribution of 
p62 varies by cell type or some other factors determine whether or not p62 is 
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incorporated into intraneuritic deposits. One underlying factor might be compartment-
dependent heterogeneity in the structure and composition of the aggregates, as observed 
for pathological tau (Liu et al. 1993, Kurt et al. 1997, Ishizawa et al. 2000). Nonetheless, 
it should be noted that if p62 promotes inclusion formation (II), the degree of p62 
incorporation might, conversely, be one factor determining the intracellular site where 
aggregated proteins pack into voluminous masses. 
In the life span of NFTs, the incorporation of p62 appears to be a relatively early event, 
since p62+ neocortical NFTs were also found in two nondemented cases with occasional 
NFTs in AT8 labeling, possibly representing preclinical AD. Consistently, NFTs 
immunoreactive for p62 were also detected in the transentorhinal cortex of a 
nondemented subject displaying only a few AT8+ NFTs in layer Pre-α cells (Braak stage 
I). Importantly, several observations suggested that p62 accumulates into NFTs before 
Ub, thereby calling for a re-evaluation of the initial model (study I) in which p62 and Ub-
conjugated proteins would co-accumulate into inclusions due to direct p62−Ub binding. 
First, in the nondemented cases, NFTs seemed to incorporate p62 before Ub (III: Table 
3), the immunoreactivity for which appears late in tangle formation (Bancher et al. 
1989a). Secondly, in the AD cases, significantly fewer NFTs labeled for Ub than for p62 
or AT8. Third, correlation data from the AD cases agreed with the interpretation that the 
p62 is incorporated into NFTs before Ub, since the regression line for Ub+ NFTs 
intersected the p62 NFT axis at a positive value (III: Fig. 2c). The opposite was seen for 
AT8+ NFTs, as expected if the aggregation of HP-tau occurs before the incorporation of 
p62. Collectively, the present findings therefore lend support to the view that p62 may 
also be engaged into inclusions in an Ub-independent manner. Nevertheless, the data are 
compatible with the possibility that upon its incorporation, p62 might promote the 
coaggregation of Ub-conjugated proteins. This would be consistent with the marked 
correlation between the numbers of p62+ and Ub+ NFTs (III: Fig. 2c). 
In summary, study III showed that in AD pathology, the immunoreactivity for p62 is 
predominantly detected in perikaryal HP-tau aggregates, i.e. NFTs, while being mostly 
absent from intraneuritic HP-tau deposits. The findings also suggested that in NFTs, p62 
is a relatively early constituent, preceding the incorporation of Ub. 
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6.5 Formation of αS-containing inclusions associated with PD (IV) 
This study elucidated the morphogenesis of nigral LBs and their relation to PaBs in cases 
with abundant inclusions in the SN, also examining the role of p62 in these pathological 
structures. The two main findings were: 1) Wide morphological heterogeneity of 
perikaryal αS-containing aggregates, ranging from punctate αS to variform compact 
inclusions (PaB- to LB-type). 2) Selective and consistent incorporation of p62 into 
compact perikaryal inclusions, combined with its absence from punctate and intraneuritic 
αS accumulation. Although several types of nigral αS accumulation have been described 
previously (Baba et al. 1998, Spillantini et al. 1998b, Wakabayashi et al. 1998a, Gomez-
Tortosa et al. 2000), the diversity observed in this study encompassed novel types and 
intermediate forms, enabling the reconstruction of a model for the formation of 
perikaryal αS-containing inclusions. 
The most inconspicuous type of αS accumulation consisted of cytoplasmic areas of 
punctate immunoreactivity, often with faint diffuse staining but lacking reactivity for p62 
or Ub, suggesting that this pattern represents the earliest immunohistochemically 
observable stage of pathological αS accumulation. Consistent with this was the 
occurrence in one of the control cases of two solitary αS+ neurons showing only punctate 
αS. To our knowledge, this type of αS-immunoreactivity has not been described 
previously in the SN. Although the αS+ granules were somewhat reminiscent of the 
“dust-like particles” detected in lower brain stem nuclei in PD (Braak et al. 2001), the 
latter were solely seen within pigment deposits, unlike the granules in our study. 
However, the diffuse αS component observed in our study might correspond to the 
“diffuse cytoplasmic” αS staining detected by Wakabayashi et al. (1998a), while the 
“cloud-like αS staining” illustrated by Gomez-Tortosa et al. (2000) appears as a more 
compact type of aggregation. Interestingly, punctate αS similar to that in our study 
accumulated in cultured cells subjected to mitochondrial inhibitors or αS overexpression 
(Lee and Lee 2002, Lee et al. 2002). 
Notably, the commonly used antibody LB509 showed no punctate staining yet clearly 
labeled compact inclusions, providing a clue into the early events of αS accumulation. 
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Since this antibody recognizes a minimum epitope at residues 115−122 of αS (Jakes et 
al. 1999), the punctate staining might represent αS modified within or close to this 
epitope, e.g. via phosphorylation at Tyr-125 or Ser-129 (Ellis et al. 2001, Fujiwara et al. 
2002). Alternatively, the punctate αS might lack the above epitope, since partially 
truncated αS was shown to be a component of LBs in DLB brains (Baba et al. 1998), and 
since C-terminal truncation enhanced the fibrillization of αS (Crowther et al. 1998). 
As regards the origins of LBs, their conspicuously spherical and concentric morphology 
would suggest two essentially opposite schemes for their formation. In the first, they 
might form by expansive, radially symmetrical growth, resulting from the deposition of 
αS and/or other proteins onto a smaller precursor body, originating from a putative 
nucleation center. However, this “growth model” would predict the existence of 
minuscule “early LBs”, but such structures were never detected in this study. Instead, 
there seemed to be a minimum diameter (~4 µm) for αS-stained LBs. Therefore, LBs are 
more likely to arise in the opposite direction, i.e. in a compaction-like manner, from a 
more voluminous yet looser precursor structure. Our data suggest that it is the PaB which 
serves as the matrix for LB formation, since a continuum of intermediate morphologies 
ranging from typical PaBs to classical LBs were found. Most importantly, peripheral 
regions of PaBs frequently contained smallish but unmistakable LBs or less distinct 
spherical masses of heightened immunoreactivity, with the appearance that focal 
compaction occurs at these sites. Similar transitional forms were ultrastructurally 
described in the locus coeruleus (Takahashi et al. 1994). In other neurons, classical LBs 
lay abutting onto what appeared to be the remains of a PaB, or as clusters with no 
intervening αS-positivity. 
The interpretation that LBs arise from PaBs is concordant with previous 
immunohistochemical studies in the SN (Wakabayashi et al. 1998a, Gomez-Tortosa et al. 
2000). Admittedly, the possibility cannot be ruled out that PaBs and LBs could reflect 
separate yet parallel aggregation processes, as interpreted by some authors before the αS 
era, based on ultrastructural and staining differences between PaBs and LBs (Pappolla et 
al. 1988, Gibb et al. 1991). However, such differences would be expected if these entities 
represent consecutive stages of a complex aggregation process. On the other hand, in our 
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study, both PaBs and LBs contained not only three common protein components (αS, 
p62, and Ub) but also in similar relative abundances, an unlikely result if PaBs and LBs 
were to originate via separate processes. 
The “compaction vs. growth” reasoning can also be applied to the origin of PaBs. 
However, their usually larger size makes it improbable that PaBs would be formed via 
compaction of a more voluminous precursor. Instead, they probably arise by growing, via 
the gradual incorporation of new material, and/or via the coalescence of already formed 
bodies into a larger mass. Therefore, irrespective of its molecular composition, the 
precursor material of PaBs should appear with diffuse or particulate morphology, or both. 
We demonstrated abundant neurons containing punctate/diffuse αS reactivity, suggesting 
that either of these components may represent the source material of PaBs. This model 
would imply that “early PaBs” should be detectable as αS+ accumulations which are 
smaller than typical PaBs yet morphologically distinct from LBs. Accordingly, such 
entities were detected in perikarya showing punctate αS, in the form of variously sized 
clump-like masses, possibly serving as “aggregation centers” that grow into typical PaBs. 
Notably, while punctate αS was never associated with p62-positivity, the latter was 
invariably present in PaBs, and was also seen in the aggregation centers. Thus, p62 seems 
to be incorporated upon PaB formation. 
Bringing together the above considerations, a pathogenetic sequence can be envisaged, 
assuming that the morphological spectrum of perikaryal αS-containing structures reflects 
a stereotypic and unidirectional aggregation process. In this scheme, punctate αS-
positivity appears in perikaryal areas of sparse neuromelanin as the earliest histologically 
observable sign of protein accumulation in the SN, consistent with the abundant evidence 
pointing to an early role for αS in the process (Lotharius and Brundin 2002). The next 
step is the appearance of a larger body within the αS-containing granules, representing 
their coalescence into a clump-like mass, whereby p62 is incorporated. These masses 
enlarge by assimilating the less aggregated αS, giving rise to what appears as a PaB. 
Concomitantly, immunoreactivity for Ub increases, likely due to the sequestration of Ub-
conjugated proteins into the growing PaB. Neuromelanin is gradually displaced by the 
PaB, which may adopt varied morphologies, possibly reflecting differences in the 
 91 
intraneuronal environment or maturation stage. Starting peripherally, the PaB undergoes 
progressive condensation, leading to the emergence of one or more spherical foci. By 
further compaction and incorporation of ambient αS+ material, these foci develop into 
classical LBs, while the remains of the PaB eventually disappear. 
The selective and consistent incorporation of p62 into PaBs and LBs is suggestive of an 
important role for p62 in their formation, supported by the presence of p62 in the 
aggregation centers. Unlike p62, Ub shows less consistent and less selective 
accumulation (Bancher et al. 1989b, Dale et al. 1992, Wakabayashi et al. 1998a), being 
variably incorporated into αS deposits in both perikarya and neurites, possibly reflecting 
a generalized buildup of Ub-conjugated proteins due to proteasomal dysfunction 
(McNaught and Jenner 2001). These findings also lend support to the view that the 
recruitment of p62 into inclusions is not dependent on Ub. 
Combined with findings from other contexts about cytoplasmic protein aggregation, the 
present observations hopefully shed more light on the significance and mechanisms of 
PaB and LB formation. It is increasingly believed that the deposition as inert inclusions 
serves as a ”third line of defence” against misfolded proteins (Zatloukal et al. 2002). 
Important supportive evidence was obtained from transgenic studies on MB formation, 
which was shown to protect hepatocytes in conditions where incorrectly assembled 
cytokeratins accumulate (Denk et al. 2000, Zatloukal et al. 2000). Since p62 is an early 
and abundant component of MBs (Stumptner et al. 2002, Zatloukal et al. 2002), its 
similar engagement in PaBs and LBs provides further evidence that also these inclusions 
confer cytoprotection against aberrant proteins. 
Consistent with the above, LBs are immunoreactive for several markers of aggresomes 
(McNaught et al. 2002b), pericentriolar deposits that form in response to cytoplasmic 
accumulation of misfolded proteins (Johnston et al. 1998, Garcia-Mata et al. 1999, 
Wigley et al. 1999). McNaught et al. therefore proposed that LB formation may represent 
an “aggresome-like response” to excess levels of unwanted proteins. However, LBs 
exhibit some notable differences compared to typical aggresomes. Most importantly, 
multiple LBs often occupy the same neuron, whereas the aggresome is, by definition, a 
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singular structure, residing in the pericentriolar area. Neither is an aggresomal response 
suggested by the highly symmetrical, spherical morphology of classical LBs. On the 
other hand, in our data, PaBs appeared to arise from punctate αS via gradually growing 
“aggregation centers” in a manner that was morphologically similar to the sequence of 
events in the prototypic aggresomal response seen in vitro (Johnston et al. 1998, Garcia-
Mata et al. 1999). Further, PaBs were usually present singly per cell. These 
considerations suggest that PaBs might be more closely related to aggresomes, whereas 
the formation of the spherical bodies (LBs) likely involves a different, yet possibly 
related, mechanism. 
In comparison to perikaryal accumulation of αS, intraneuritic deposits exhibited two 
marked differences. Unlike inclusions in perikarya, intraneuritic deposits were 
consistently immunonegative for p62, and far fewer abnormal neurites were stained than 
for αS or Ub. Interestingly, this predilection of p62 for perikaryal aggregates duplicated 
the analogous findings on AD-type tau pathology (III). There was a further difference to 
perikaryal accumulation; no punctate αS was detected at extrasomal sites. These findings 
may suggest that intraneuritic αS inclusions form via a mechanism fundamentally 
different from perikaryal inclusions. 
An unexpected finding in study IV was the copious presence of p62 in MarBs. Although 
their origin and pathological significance remain obscure (Beach et al. 2004), nigral 
MarBs were shown to be increased after severe agonal psychophysiological stress, 
suggesting that MarBs may result from stress at the neuronal level, such as energy crisis 
or excitotoxicity (Quan et al. 2001a, Quan et al. 2001b). This possibility is consistent 
with the engagement of p62, the expression of which is upregulated upon stressful 
conditions (p. 76). Of possible relevance, activators of the stress-related protein kinase 
p38 were reported to induce the nuclear translocation of p62 (Sudo et al. 2000). The 
presence of p62 in MarBs could also indicate that the recruitment of p62 is not confined 
to cytoplasmic inclusions but rather may represent a more general event, triggered by 
protein aggregates whether in the cytosol or the topologically equivalent nucleoplasm. 
This finding therefore predicts that one would find the incorporation of p62 also in the 
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morphologically similar intranuclear inclusions seen in polyglutamine expansion 
diseases. 
Taken together, the results of study IV suggest that in the SN, punctate perikaryal αS, 
PaBs, and LBs originate as successive stages of a complex aggregation process. The 
early and consistent involvement of p62 in this process supports the view that the 
formation of PaBs and LBs represents a cytoprotective response against the accumulation 
of noxious proteins. 
 Table 4. Relation of p62 to primary constituents and Ub in pathological inclusions. 
Inclusion type 
Assumed primary 
constituents 
(candidates) 
p62 vs. primary 
constituent 
Ub vs. primary 
constituent p62 vs. Ub Reference 
 
 
 
 
neurofibrillary tangle (AD) tau mostly p62+ Ub late component p62 precedes & 
outnumbers Ub 
Study III  
 
 
Pick body tau p62 weaker Ub weaker similar Study II  
 
tau+ glial inclusions (PSP, CBD) tau n/a Ub weaker / absent p62 stronger? Arai et al. 2003  
glial cytoplasmic inclusion (MSA) α-synuclein similar      similar similar Study II
pale body α-synuclein p62 already present 
in the earliest PaBs 
variable p62 stronger Study IV  
 
 
Lewy body (brainstem-type) α-synuclein ~identical numbers mostly Ub+ similar Study IV  
Ub+ neuronal inclusions 
(FTD, ALS-D) 
? (p62) ? ? similar / 2Ub 
outnumbers p62 
Arai et al. 2003, 
Nakano et al. 2004 
 
 
 
Ub− glial inclusions (ALS-D) ? (p62) ? all Ub− only p62 present Arai et al. 2003  
Rosenthal fiber GFAP mostly p62+ mostly Ub+ n/a Zatloukal et al. 2002  
intracytoplasmic hyaline body ? (p62) p62 = the primary 
constituent? 
mostly Ub− p62 much stronger 
& outnumbers Ub 
Stumptner et al. 1999  
 
 
Mallory body cytokeratins and p62 p62 already present 
in the earliest MBs 
mostly Ub+ p62 precedes & 
outnumbers Ub 
Stumptner et al. 2002, 
Zatloukal et al. 2002  
 
1Marinesco body ? (ataxin-3, p62)  ? ? p62 outnumbers Ub Study IV  
n/a = not analyzed. Bold type indicates results based on quantitative or temporal analyses. 
1No overt disease association to date. 2The result may be affected by suboptimal detection of p62 (see p. 84).
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6.6 Possible roles of p62 in protein aggregation 
The role of p62 in cytoplasmic inclusions is enigmatic. Based on the findings to date, the 
presence of p62 appears to be a general feature in pathological proteinaceous inclusions 
lacking delimiting membranes (Table 4). This generality suggests that the involvement of 
p62 in inclusions might indicate a functional role that provides adaptive value and could 
thereby have been moulded by evolution. Such a functional involvement might not be 
restricted to disease-associated protein deposition but could also be of importance in non-
pathological conditions where proteins may accumulate, for example during cellular 
differentiation. 
Although several studies have indicated a role for p62 in the regulation of aPKC, this 
does not preclude additional functions for p62. In fact, there is a growing list of well-
characterized proteins performing two or more different functions. These “moonlighting 
proteins” are involved in diverse cellular systems and include receptor, chaperone, 
proteasomal, and regulatory proteins (Jeffery 1999, Jeffery 2003). While some of them 
seem to provide a means for coordinating related cellular activities, in other cases there is 
no overt connection between their different functions. Thus, the recruitment to inclusions 
might reflect a second function for p62, possibly unrelated to the aPKC context. 
Interestingly, the mechanisms whereby a multifunctional protein can switch between 
functions include complex formation and oligomerization (Jeffery 1999, Jeffery 2003). 
Alternatively, the involvement of p62 might represent an epiphenomenon in the 
evolutionary sense, i.e., an event that is dictated by the structural and functional 
properties of p62 yet has not been shaped by evolutionary selection. While this issue has 
both practical and theoretical implications, at present too little data is available for 
judging between these possibilities. Be the evolutionary aspect as it may, the key 
questions from the pathogenetic standpoint remain the same and concern the mechanisms 
underlying, and the significance of p62 involvement in cytoplasmic inclusions. The 
findings accrued to date are compatible with several possible scenarios, where the effect 
of p62 on inclusion formation ranges from promoting through neutral to antagonizing. 
Conceivable mechanisms comprise both “p62-autonomous” ones (i.e., not prescribing the 
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engagement of additional proteins) as well as scenarios involving p62 as part of more 
complex, organized responses. 
As discussed above (p. 85), currently available evidence suggests that the apparent 
affinity of p62 for protein aggregates (whether resulting from its binding to Ub or to 
other molecules therein) may act in concert with the oligomerization of p62 to favor the 
compaction of aggregated proteins into dense inclusions. Although this view may be 
intuitively appealing, it should be noted that at present there is no direct evidence for the 
presumed promoting effect of p62. Resolving this issue will require work on 
experimental models of inclusion formation, where the consequences of interfering with 
p62 function can be directly assayed. 
It is also possible that the incorporation of p62 might have essentially no effect on the 
process of inclusion formation. Nevertheless, even if such “passive entrapment” might be 
a mere epiphenomenon for inclusion formation, it might interfere with the function of 
p62 as an adaptor in receptor-activated signaling and as a scaffold for aPKC. In 
polyglutamine expansion diseases, the depletion of vital signaling intermediates by 
sequestration into intranuclear inclusions appears to contribute to the pathogenesis 
(Nucifora et al. 2001, Chai et al. 2002, Qin et al. 2004). At least in a model of 
(intranuclear) polyglutamine aggregates, p62 was redistributed from its normal cytosolic 
locale to the inclusions (Donaldson et al. 2003). If cytoplasmic inclusions cause a similar 
depletion of p62, this might disrupt pro-survival signaling (e.g., via NF-κB and ERK5), 
since p62 is thought to play an important role in mediating the responsivity to 
neurotrophic factors such as NGF, NT-3, NT-4/5, and BDNF (Samuels et al. 2001, 
Wooten et al. 2001, Mamidipudi et al. 2002, Geetha and Wooten 2003). On the other 
hand, it is unclear if the effect would be deleterious to the cell, since p62-deficient mice 
were reportedly born “grossly normal” without any overt anatomic abnormalities (Duran 
et al. 2004). However, p62 might figure more prominently in pathological conditions. 
It has also been speculated that p62 could play a role in masking hydrophobic surfaces on 
aggregated proteins (Zatloukal et al. 2002), thereby preventing detrimental interactions 
with other cellular constituents. In this role, p62 would thus function in a chaperone-like 
manner. Moreover, p62 might act in a way that would promote the disaggregation of 
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inclusion components, as observed for molecular chaperones in experimental models 
(e.g., Koyama and Goldman 1999, Cummings et al. 2001, Abu-Baker et al. 2003). Here, 
p62 might even aid in the targeting of aggregated proteins for proteolysis, since in the 
receptor-signaling context, the p62 ligand TRAF6 has a Ub ligase activity (Deng et al. 
2000). Thus, the role of p62 could be analogous to that of heat shock protein 70, which 
recognizes misfolded proteins and enables their ubiquitination by the co-chaperone Chip-
1, predisposing the tagged proteins for degradation (Meacham et al. 2001, Chavez Zobel 
et al. 2003). 
The p62 protein might also be part of a more complex mechanism promoting 
aggregation. In view of its presence in diverse inclusions, the possible involvement of 
p62 in the aggresomal response is an intriguing possibility. Several aspects of the 
aggresomal mechanism are unclear (Garcia-Mata et al. 2002), pointing to the 
involvement of as yet unidentified factors. For example, it is poorly understood how 
abnormal proteins are recognized and taken up for delivery into the aggresome (Johnston 
et al. 2002). In view of its Ub-binding ability, p62 has been put forward to be a strong 
candidate for the binding of Ub-conjugated proteins to MTs and recruiting them to the 
pericentriolar area (Wilkinson 2000). However, such a function was recently identified 
for another protein, histone deacetylase 6 (HDAC6), which was shown to link 
polyubiquitinated misfolded proteins to dynein motors (Kawaguchi et al. 2003). On the 
other hand, HDAC6 only appeared to be crucial for the formation of polyubiquitin-
enriched aggresomes, while neither the formation of aggresomes in vitro (Garcia-Mata et 
al. 1999, Johnston et al. 2000) nor the incorporation of p62 into inclusions seems to 
require polyubiquitin. Therefore, p62 might play an analogous role in the recognition of 
misfolded proteins in an Ub-independent manner. 
Regardless of the specific function that p62 might serve in the aggresomal response, the 
involvement of p62 is suggested by the finding that it accumulates early and abundantly 
into MBs (Stumptner et al. 2002, Zatloukal et al. 2002) which display some aggresomal 
features (Riley et al. 2002, Riley et al. 2003a, Riley et al. 2003b). However, it should be 
noted that MBs differ from typical aggresomes by being irregularly shaped and often 
present as multiple bodies per cell (Denk et al. 2001). Although this disparity might be 
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due to the disruption of the MT array by the aggregating cytokeratins (Nakamichi et al. 
2002), the relation of MBs to aggresomes remains to be defined. 
In the case of neuropathological cytoplasmic inclusions, most of which also seem to 
incorporate p62 (Table 4), it is likewise unclear to what extent an aggresomal mechanism 
might contribute to their formation. The only type for which there is published evidence 
from human postmortem studies for aggresomal involvement is the LB (McNaught et al. 
2002b) which, nevertheless, exhibits clearcut differences from aggresomes formed in 
vitro by diverse aggregation-prone proteins (pp. 91−92). Similarly, most types of tau-
enriched inclusions display morphologies seemingly disparate with in vitro aggresomes. 
This is not surprising, since tau pathology is accompanied by a breakdown of the MT 
network, at least in AD (Iqbal et al. 1998), thus disrupting the MT-dependent transport 
necessary for aggresome formation. However, tau inclusions, as well as MBs, might 
represent an aggresomal response gone awry. 
Our data suggested at least a morphological similarity between the formation of PaBs and 
aggresomes (IV). The recruitment of p62 upon the emergence of “aggregation centers” would 
thus agree with a possible role in aggresome formation. On the other hand, the presence of 
p62 also in the intranuclear MarBs (IV) would argue against a specific role in the aggresomal 
response, rather suggesting that whatever mechanistic role p62 has in inclusion formation, it 
is likely to affect protein aggregation whether in the cytosol or nucleoplasm. 
While the above scenarios are based on the known structural and functional properties of 
p62, it is also possible that the incorporation of p62 into inclusions involves a major 
structural change in p62, resulting in its conversion to β-sheet-enriched fibrils as is the 
case with tau and αS. There is increasing evidence suggesting that the ability to form β-
sheet-rich fibrils is a generic property of proteins (Dobson 2001), including globular ones 
mostly composed of α helices (Fändrich et al. 2001). The putative fibrils of p62 might 
represent a minor or major constituent of the aggregate, depending on the inclusion type. 
This possibility is intriguing in view of the partially filamentous ultrastructure of IHBs 
(MacDonald and Bedard 1990), where p62 is the only abundant constituent identified to 
date. Further, since structurally unrelated proteins such as tau and αS may synergistically 
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promote mutual fibrillization (Giasson et al. 2003), it is conceivable that misfolded, 
fibrillar proteins might also trigger fibril formation from p62. 
Although there are various possible ways to explain the role of p62 in cytoplasmic 
inclusions, parsimony argues for the simplest explanations, especially in view of the 
current lack of supporting evidence for roles in mechanisms assuming more complex 
organization (e.g., disaggregation or aggresomal responses). Thus, findings to date favor 
the p62-autonomous scenarios that require the minimum of novel interactions. The 
simplest explanation for the presence of p62 in diverse inclusions containing different 
pimary constituents, with or without Ub, is that the incorporation of p62 is due to binding 
to Ub or some other molecular determinant(s) associated with misfolded, aggregated 
proteins. Regardless of the identity of the target (e.g., hydrophobic surfaces, oxidized 
residues, β-sheet conformation, chaperone proteins, or Ub-conjugated species), the 
binding of p62, combined with its propensity for oligomerization, would be expected to 
lead to strong, multivalent interaction of p62 arrays with the aggregated proteins. Some 
of the p62 thus incorporated might expose free binding surfaces for aberrant proteins, 
chaperones, or Ub, expediting the further entrapment and deposition of misfolded and/or 
ubiquitinated proteins in a glue-like manner. This process might be promoted by the 
upregulation of p62 due to proteasomal dysfunction and/or oxidative stress (study I). 
While in most types of inclusions studied, the incorporation of p62 seems to be 
precipitated by the primary constituent (e.g., HP-tau, αS), in other types, p62 itself might 
constitute the initial and main component (e.g., IHBs, Ub− glial inclusions). 
Taken together, the conceivable roles for p62 in cytoplasmic inclusions remain open to 
speculation. However, the simplest interpretations of the present findings favor the view 
that p62 has a structural propensity for oligomeric association with aggregates of 
misfolded and/or ubiquitinated proteins. Thereby, p62 likely enhances their deposition 
into compact masses in both cytosolic and nuclear compartments. Since mounting 
evidence suggests that inclusions serve as structures which sequester potentially noxious 
proteins, the coaggregation of p62 may promote the survival of inclusion-containing cells 
in tauopathies and synucleinopathies, as well as in other diseases involving protein 
aggregation. 
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7. CONCLUSIONS 
This series of studies was carried out to identify a candidate protein (p62) possibly 
involved in neurodegenerative phenomena, and to characterize its involvement in 
disease-associated protein aggregation in the human brain. 
The following conclusions can be drawn: 
1) In neuronal culture, the expression levels of p62 mRNA and protein are prominently 
upregulated in response to pro-apoptotic conditions and proteasomal inhibition. At 
least in the former case, p62 upregulation might contribute to pro-survival signaling. 
2) In human tauopathies (Alzheimer and Pick diseases) and synucleinopathies 
(Parkinson disease, dementia with Lewy bodies, and multiple system atrophy), the 
p62 protein is copiously present in the hallmark cytoplasmic inclusions and is mostly 
confined to perikaryal deposits. 
3) In the tau pathology of Alzheimer disease, p62 is selectively incorporated into 
neurofibrillary tangles and is a relatively early constituent of these structures. 
4) The spectrum of nigral αS pathology characteristic of Parkinson disease suggests a 
morphogenetic sequence in which punctate αS deposits, pale bodies, and Lewy 
bodies arise as successive stages of a complex aggregation process. The engagement 
of p62 seems to coincide with the formation of compact inclusions. 
These findings are compatible with several alternative interpretations. However, 
combined with other relevant research, the present observations favor the view that the 
incorporation of p62 may enhance the deposition of aggregated proteins into compact 
inclusions. This presumed role of p62 encompasses both perikaryal tau- and αS-
containing inclusions while appearing to be of a more general nature. In light of the 
mounting evidence that the sequestration of potentially noxious proteins into a discrete 
body may minimize their deleterious effects, p62 may thus serve to promote cell viability. 
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